###begin article-title 0
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 53 58 <span type="species:ncbi:9606">human</span>
Functional characterization of alternatively spliced human SECISBP2 transcript variants
###end article-title 0
###begin p 1
Present addresses: Junning Wang, Harvard Medical School-Partners Healthcare Center for Genetics and Genomics (HPCGG), New Research Building, Room 164, 77 Avenue Louis Pasteur, Boston MA 02115. Ravindra N. Singh, Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
###end p 1
###begin p 2
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 392 400 392 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 537 546 537 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 551 558 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 614 622 614 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 687 695 687 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 918 925 918 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 306 312 <span type="species:ncbi:9606">humans</span>
###xml 681 686 <span type="species:ncbi:9606">human</span>
Synthesis of selenoproteins depends on decoding of the UGA stop codon as the amino acid selenocysteine (Sec). This process requires the presence of a Sec insertion sequence element (SECIS) in the 3'-untranslated region of selenoprotein mRNAs and its interaction with the SECIS binding protein 2 (SBP2). In humans, mutations in the SBP2-encoding gene Sec insertion sequence binding protein 2 (SECISBP2) that alter the amino acid sequence or cause splicing defects lead to abnormal thyroid hormone metabolism. Herein, we present the first in silico and in vivo functional characterization of alternative splicing of SECISBP2. We report a complex splicing pattern in the 5'-region of human SECISBP2, wherein at least eight splice variants encode five isoforms with varying N-terminal sequence. One of the isoforms, mtSBP2, contains a mitochondrial targeting sequence and localizes to mitochondria. Using a minigene-based in vivo splicing assay we characterized the splicing efficiency of several alternative transcripts, and show that the splicing event that creates mtSBP2 can be modulated by antisense oligonucleotides. Moreover, we show that full-length SBP2 and some alternatively spliced variants are subject to a coordinated transcriptional and translational regulation in response to ultraviolet type A irradiation-induced stress. Overall, our data broadens the functional scope of a housekeeping protein essential to selenium metabolism.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 363 366 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 943 944 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1133 1134 1133 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1240 1248 1240 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">[Ser]Sec</sup>
###xml 1249 1250 1249 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1303 1304 1303 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1350 1351 1350 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1352 1353 1352 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1395 1396 1395 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1397 1399 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1488 1490 1488 1490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Selenocysteine (Sec), the 21st amino acid in the genetic code, is incorporated into a subset of proteins termed selenoproteins in response to an in-frame UGA codon (1). Since the UGA codon most commonly signals translation termination, its decoding as Sec relies on the presence of several unique, evolutionary conserved structures and protein factors. The major cis-acting determinant for Sec incorporation is the Sec insertion sequence (SECIS) element, a stem-loop RNA structure located within the 3'-untranslated region (UTR) of all eukaryotic selenoprotein mRNAs (2,3). This element acts by recruiting the specialized protein complexes required for the read-through of UGA and translation of selenoproteins. An additional RNA structure able to support UGA codon read-through, named the Sec redefinition element (SRE), has been recently identified within the coding region of selenoprotein N, a few nucleotides downstream of the UGA codon (4). While the SECIS element is absolutely required for Sec incorporation, the SRE appears to play only a fine-tuning role in determining the UGA decoding efficiency for some selenoproteins (5). Synthesis, delivery and incorporation of Sec into polypeptide chains is supported by selenocysteyl-tRNA[Ser]Sec(1) and by a set of specialized proteins [reviewed in (6)], including SECIS binding protein 2 (SBP2) (7,8), Sec-specific elongation factor eEFSec (9,10), ribosomal protein L30 (11), the 43 kDa RNA binding protein (SECp43) and Sec synthase (12). Although much progress has been made in delineating individual components required for selenoprotein synthesis, the overall mechanism that directs this process is not fully understood.
###end p 5
###begin p 6
###xml 141 149 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 375 383 375 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 447 454 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 584 592 584 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 224 229 <span type="species:ncbi:9606">human</span>
SBP2 is one of the most studied selenoprotein synthesis factors, initially shown to be required for this process in reticulocyte lysates and in vitro assays (8,13). Consistent with this, we have shown that SBP2 depletion in human cells leads to decreased selenoprotein synthesis (14). Hereafter, we refer to SBP2 as protein, whereas Sec insertion sequence binding protein 2 (SECISBP2) in italicized letters refers to gene or transcript. The first in vivo evidence showing that SBP2 is epistatic to selenoprotein synthesis was recently provided in a study that identified mutations in SECISBP2 in families presenting with clinical evidence of abnormal thyroid hormone metabolism (15). This was manifested through lack of functional selenoenzyme deiodinase 2 (DIO2) and dramatically reduced levels of selenoprotein P in affected individuals (15). Detailed biochemical and functional characterization of SBP2 has been carried out; however, its regulation at the gene and transcript level requires further studies.
###end p 6
###begin p 7
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1049 1054 1049 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20 B21 B22 B23 B24">20&#8211;24</xref>
###xml 718 723 <span type="species:ncbi:9606">human</span>
###xml 934 939 <span type="species:ncbi:9606">human</span>
###xml 1036 1041 <span type="species:ncbi:9606">human</span>
Alternative splicing represents a functionally important and a major regulatory pathway of gene expression and ultimately protein function. Recent genomic studies have indicated that at least 60% of mammalian genes are subjected to alternative splicing (16), providing a significant contribution to protein diversity beyond that encoded in the genome sequence. Most alternative splicing events affect the coding sequence and it is believed that half of these alter the reading frame (17), and a third lead to nonsense mediated decay (NMD) of the RNA product (18). Defects in alternative splicing and generation of aberrant ratios of mRNA transcripts from a single gene are now also recognized as major contributors to human disease and it is estimated that at least 15% of the mutations that cause hereditary disease affect pre-mRNA splicing (19). Splicing defects have also been associated with cancers and a genome wide analysis of human expressed sequence tags (ESTs) found strong evidence for cancer specific splice variants in 316 human genes (20-24). To date, this level of regulation has not been explored for any of the factors involved in Sec incorporation, including SBP2.
###end p 7
###begin p 8
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 186 194 186 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 601 610 601 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 670 678 670 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 773 781 773 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 983 991 983 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1054 1061 1054 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1260 1271 1260 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2)</italic>
###xml 1303 1310 1303 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1384 1392 1384 1392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1421 1431 1421 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1543 1553 1543 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 767 772 <span type="species:ncbi:9606">human</span>
SBP2 is the only protein of the Sec incorporation machinery so far linked to a clinical condition (15). Interestingly, one of the mutations identified in patients alters the splicing of SECISBP2 by creating an alternative donor splice site, which produces a transcript with a 26 bp intron retention. This event alters the reading frame upstream of the SBP2 RNA-binding domain, giving rise to a truncated, non-functional protein. The regulation of SBP2 expression by alternative splicing thus appears to have significant implications for its function. Prompted by these findings, we herein carried out in silico, as well as functional analysis of alternative splicing of SECISBP2. We now provide evidence for a complex alternative splicing pattern in the 5'-region of human SECISBP2 that give rise to eight spliced variants generated through different exon combinations. All alternative splicing events are confined within the region of SBP2 that is dispensable for Sec incorporation in vitro, but may be involved in regulation of selenoprotein synthesis in vivo. Interestingly, one of the alternatively spliced isoforms contains a mitochondrial targeting sequence (MTS). We designated this transcript as mitochondrial Sec insertion sequence binding protein 2 (mtSECISBP2). First, using a minigene-based in vivo splicing assay we delineated the splicing events within the 5'-region of SECISBP2 and showed that splicing of mtSECISBP2 can be modulated by antisense oligonucleotides (ASOs). We furthermore demonstrated that the protein encoded by mtSECISBP2 does indeed localize to mitochondria and that transcription and translation of SBP2 is regulated in a coordinated manner in response to stress.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In silico</italic>
In silico identification of alternatively spliced forms of SBP2
###end title 10
###begin p 11
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 213 221 213 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 456 464 456 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 207 212 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
The previously characterized human full-length SECISBP2 gene (GeneBank ID: NM_024077) was used to search against both the EST and the non-redundant (NR) nucleotide databases to identify alternative forms of human SECISBP2 gene. Sequence analyses were performed using BLAST programs (available at ) with default parameters. Tissue- and cell-type information of various ESTs was also retrieved from EST database. Identified sequences that were homologous to SECISBP2 were then mapped to human genomic sequences to analyze genomic structures of detected alternative forms. Cellular localizations of proteins were predicted by PSORT II ().
###end p 11
###begin title 12
Cell culture and treatments
###end title 12
###begin p 13
###xml 334 335 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 503 504 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 213 217 <span type="species:ncbi:9913">calf</span>
The cell lines human embryonic kidney 293T, human cervical carcinoma C33A, human cervical carcinoma HeLa and normal foreskin fibroblast (NFF) cells, were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (Gibco-BRL, Gaithersburg, MD, USA) and 1% penicillin/streptomycin, in a humidified atmosphere containing 5% CO2. For Ultraviolet A (UVA) treatments, media was removed and kept at 37degreesC, and phosphate buffered saline (PBS) was added. Cells were subjected to a dose of 50 kJ/m2 of UVA irradiation. Control cells were maintained in PBS at room temperature, in the dark, for the duration of treatment. Following irradiation, the PBS was replaced with the media and cells were allowed to recover for the time indicated.
###end p 13
###begin title 14
Generation of minigenes
###end title 14
###begin p 15
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pfx</italic>
###xml 518 526 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 846 848 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1001 1009 965 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1194 1203 1158 1167 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1237 1245 1201 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1267 1270 1231 1234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 1295 1303 1259 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1412 1415 1376 1379 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 1438 1446 1402 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1838 1841 1802 1805 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 1203 2036 1167 2000 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="16">Schematic representation of human <italic>SECISBP2</italic> transcript variants. <bold>(A)</bold> Genomic organisation of <italic>SECISBP2</italic> showing the 17 exons and their sizes in base pairs (bp). Locations of the functional domains are indicated. <bold>(B)</bold> Alternatively spliced <italic>SECISBP2</italic> transcript variants generated through different exon combinations are shown schematically. Arrowheads indicate translation start sites. Designation for the encoded protein isoforms, the corresponding Met start codon number [based on numbering in the full-length human SBP2 sequence (NP_076982)] and predicted molecular weights (MW) of isoforms are indicated to the right of each transcript. <bold>(C)</bold> An alternative reading frame used for translation of the mitochondrial SBP2 isoform (mtSBP2) initiates in exon 2 (indicated by arrow). The encoded mitochondrial targeting sequence is underlined.</p>
###xml 1203 2036 1167 2000 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="16">Schematic representation of human <italic>SECISBP2</italic> transcript variants. <bold>(A)</bold> Genomic organisation of <italic>SECISBP2</italic> showing the 17 exons and their sizes in base pairs (bp). Locations of the functional domains are indicated. <bold>(B)</bold> Alternatively spliced <italic>SECISBP2</italic> transcript variants generated through different exon combinations are shown schematically. Arrowheads indicate translation start sites. Designation for the encoded protein isoforms, the corresponding Met start codon number [based on numbering in the full-length human SBP2 sequence (NP_076982)] and predicted molecular weights (MW) of isoforms are indicated to the right of each transcript. <bold>(C)</bold> An alternative reading frame used for translation of the mitochondrial SBP2 isoform (mtSBP2) initiates in exon 2 (indicated by arrow). The encoded mitochondrial targeting sequence is underlined.</p></caption>
###xml 2036 2036 2000 2000 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn829f1"/>
###xml 1194 2036 1158 2000 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="16">Schematic representation of human <italic>SECISBP2</italic> transcript variants. <bold>(A)</bold> Genomic organisation of <italic>SECISBP2</italic> showing the 17 exons and their sizes in base pairs (bp). Locations of the functional domains are indicated. <bold>(B)</bold> Alternatively spliced <italic>SECISBP2</italic> transcript variants generated through different exon combinations are shown schematically. Arrowheads indicate translation start sites. Designation for the encoded protein isoforms, the corresponding Met start codon number [based on numbering in the full-length human SBP2 sequence (NP_076982)] and predicted molecular weights (MW) of isoforms are indicated to the right of each transcript. <bold>(C)</bold> An alternative reading frame used for translation of the mitochondrial SBP2 isoform (mtSBP2) initiates in exon 2 (indicated by arrow). The encoded mitochondrial targeting sequence is underlined.</p></caption><graphic xlink:href="gkn829f1"/></fig>
###xml 2036 2045 2000 2009 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 2045 2053 2009 2017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2095 2102 2059 2066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2119 2122 2083 2086 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 2342 2345 2306 2309 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 2378 2386 2342 2350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2598 2601 2562 2565 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 2601 2608 2565 2572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 2629 2637 2593 2601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2675 2677 2635 2637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 3206 3214 3166 3174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 3276 3286 3236 3246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 3432 3435 3392 3395 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D)</bold>
###xml 3509 3517 3469 3477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 3522 3532 3482 3492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 3615 3625 3575 3585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 3662 3670 3622 3630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2045 3682 2009 3642 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="17"><italic>SECISBP2</italic> transcript expression and minigene-based <italic>in vivo</italic> splicing assay. <bold>(A)</bold> Relative expression levels of full-length and mitochondrial SBP2 transcripts in a cDNA panel of human tissues was analyzed by real-time PCR using transcript specific primers. Data was analyzed using the deltaCT method. <bold>(B)</bold> Schematic representation of the <italic>SECISBP2</italic> minigene indicating exon/intron composition, location of primers used to amplify the minigene-expressed products, annealing site for antisense oligonucleotides (In2E3a ASO) and location of mutations introduced. <bold>(C)</bold><italic>In vivo</italic> splicing pattern of <italic>SECISBP2</italic> minigene constructs. RT-PCR of &#945;-<sup>32</sup>P-dCTP labeled products were amplified from C33A cells transfected with wild-type (WT), exon 2 ATG&gt;CTG mutant (Ex2ATG&gt;CTG) and exon 3 AG&gt;AA mutant (Ex3AG&gt;AA) minigenes. The exon combination as verified by sequencing is indicated on the left (products indicated by * are predicted only). Mutation at the exon 3a acceptor site AG&gt;AA abolishes splicing between exon 2 and exon 3b as shown by the absence of exon 2&#8211;3b spliced product (lane 2). In2E3a ASO treatment almost completely abrogates exon 2&#8211;3a splicing and thus full-length <italic>SECISBP2</italic> transcript and dramatically increases exon 2&#8211;3b splicing and <italic>mtSECISBP2</italic> transcript levels (lane 4). Percentage of exon 3a skipping was calculated from the total value of exon 3a-included and exon 3a-skipped products. <bold>(D)</bold> Normal human fibroblast cells were treated with In2E3a ASO and levels of <italic>SECISBP2</italic> and <italic>mtSECISBP2</italic> were measured by real-time RT-PCR. In2E3a-treated cells show a 4-fold increase in <italic>mtSECISBP2</italic> and 50% decrease in the full-length <italic>SECISBP2</italic> transcript.</p>
###xml 2045 3682 2009 3642 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="17"><italic>SECISBP2</italic> transcript expression and minigene-based <italic>in vivo</italic> splicing assay. <bold>(A)</bold> Relative expression levels of full-length and mitochondrial SBP2 transcripts in a cDNA panel of human tissues was analyzed by real-time PCR using transcript specific primers. Data was analyzed using the deltaCT method. <bold>(B)</bold> Schematic representation of the <italic>SECISBP2</italic> minigene indicating exon/intron composition, location of primers used to amplify the minigene-expressed products, annealing site for antisense oligonucleotides (In2E3a ASO) and location of mutations introduced. <bold>(C)</bold><italic>In vivo</italic> splicing pattern of <italic>SECISBP2</italic> minigene constructs. RT-PCR of &#945;-<sup>32</sup>P-dCTP labeled products were amplified from C33A cells transfected with wild-type (WT), exon 2 ATG&gt;CTG mutant (Ex2ATG&gt;CTG) and exon 3 AG&gt;AA mutant (Ex3AG&gt;AA) minigenes. The exon combination as verified by sequencing is indicated on the left (products indicated by * are predicted only). Mutation at the exon 3a acceptor site AG&gt;AA abolishes splicing between exon 2 and exon 3b as shown by the absence of exon 2&#8211;3b spliced product (lane 2). In2E3a ASO treatment almost completely abrogates exon 2&#8211;3a splicing and thus full-length <italic>SECISBP2</italic> transcript and dramatically increases exon 2&#8211;3b splicing and <italic>mtSECISBP2</italic> transcript levels (lane 4). Percentage of exon 3a skipping was calculated from the total value of exon 3a-included and exon 3a-skipped products. <bold>(D)</bold> Normal human fibroblast cells were treated with In2E3a ASO and levels of <italic>SECISBP2</italic> and <italic>mtSECISBP2</italic> were measured by real-time RT-PCR. In2E3a-treated cells show a 4-fold increase in <italic>mtSECISBP2</italic> and 50% decrease in the full-length <italic>SECISBP2</italic> transcript.</p></caption>
###xml 3682 3682 3642 3642 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn829f2"/>
###xml 2036 3682 2000 3642 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="17"><italic>SECISBP2</italic> transcript expression and minigene-based <italic>in vivo</italic> splicing assay. <bold>(A)</bold> Relative expression levels of full-length and mitochondrial SBP2 transcripts in a cDNA panel of human tissues was analyzed by real-time PCR using transcript specific primers. Data was analyzed using the deltaCT method. <bold>(B)</bold> Schematic representation of the <italic>SECISBP2</italic> minigene indicating exon/intron composition, location of primers used to amplify the minigene-expressed products, annealing site for antisense oligonucleotides (In2E3a ASO) and location of mutations introduced. <bold>(C)</bold><italic>In vivo</italic> splicing pattern of <italic>SECISBP2</italic> minigene constructs. RT-PCR of &#945;-<sup>32</sup>P-dCTP labeled products were amplified from C33A cells transfected with wild-type (WT), exon 2 ATG&gt;CTG mutant (Ex2ATG&gt;CTG) and exon 3 AG&gt;AA mutant (Ex3AG&gt;AA) minigenes. The exon combination as verified by sequencing is indicated on the left (products indicated by * are predicted only). Mutation at the exon 3a acceptor site AG&gt;AA abolishes splicing between exon 2 and exon 3b as shown by the absence of exon 2&#8211;3b spliced product (lane 2). In2E3a ASO treatment almost completely abrogates exon 2&#8211;3a splicing and thus full-length <italic>SECISBP2</italic> transcript and dramatically increases exon 2&#8211;3b splicing and <italic>mtSECISBP2</italic> transcript levels (lane 4). Percentage of exon 3a skipping was calculated from the total value of exon 3a-included and exon 3a-skipped products. <bold>(D)</bold> Normal human fibroblast cells were treated with In2E3a ASO and levels of <italic>SECISBP2</italic> and <italic>mtSECISBP2</italic> were measured by real-time RT-PCR. In2E3a-treated cells show a 4-fold increase in <italic>mtSECISBP2</italic> and 50% decrease in the full-length <italic>SECISBP2</italic> transcript.</p></caption><graphic xlink:href="gkn829f2"/></fig>
###xml 1231 1236 <span type="species:ncbi:9606">human</span>
###xml 1709 1714 <span type="species:ncbi:9606">human</span>
###xml 2219 2224 <span type="species:ncbi:9606">human</span>
###xml 3443 3448 <span type="species:ncbi:9606">human</span>
SECISBP2 minigene splicing cassette was generated by amplifying genomic sequences starting from exon 1 through exon 4 of the SECISBP2 gene with high-fidelity Pfx polymerase (Invitrogen, Carlsbad, CA, USA) and genomic DNA (Clontech Laboratories, Inc. Palo Alto, CA, USA). Appropriate primers were used to reduce the size of intron 2 from approximately5.6 kb to 356 nt that include 184 residues of the 5'-end of intron 2 and 172 residues of the 3'-end of intron 2. An approximately2.3 kb amplified fragment from genomic SECISBP2 containing entire exon 1, entire intron 1, entire exon 2, partial intron 2 (only 356 nt), entire exon 3, entire intron 3 and entire exon 4 was cloned into pCI vector (Promega) between Xho I and Not I site. Subsequently, genomic sequences from the pCI vector were subcloned into a SBP2-GFP plasmid described previously (14). Here, appropriate primers were used to replace exon 1 through exon 4 of SBP2 cDNA sequence with approximately2.3 kb genomic sequence described above (Figure 2A). The complete SBP2 minigene sequence is provided as . Mutations were introduced using the Quick-Change site directed mutagenesis kit (Stratagene) as per manufacturer's instructions. Figure 1.Schematic representation of human SECISBP2 transcript variants. (A) Genomic organisation of SECISBP2 showing the 17 exons and their sizes in base pairs (bp). Locations of the functional domains are indicated. (B) Alternatively spliced SECISBP2 transcript variants generated through different exon combinations are shown schematically. Arrowheads indicate translation start sites. Designation for the encoded protein isoforms, the corresponding Met start codon number [based on numbering in the full-length human SBP2 sequence (NP_076982)] and predicted molecular weights (MW) of isoforms are indicated to the right of each transcript. (C) An alternative reading frame used for translation of the mitochondrial SBP2 isoform (mtSBP2) initiates in exon 2 (indicated by arrow). The encoded mitochondrial targeting sequence is underlined.Figure 2.SECISBP2 transcript expression and minigene-based in vivo splicing assay. (A) Relative expression levels of full-length and mitochondrial SBP2 transcripts in a cDNA panel of human tissues was analyzed by real-time PCR using transcript specific primers. Data was analyzed using the deltaCT method. (B) Schematic representation of the SECISBP2 minigene indicating exon/intron composition, location of primers used to amplify the minigene-expressed products, annealing site for antisense oligonucleotides (In2E3a ASO) and location of mutations introduced. (C)In vivo splicing pattern of SECISBP2 minigene constructs. RT-PCR of alpha-32P-dCTP labeled products were amplified from C33A cells transfected with wild-type (WT), exon 2 ATG>CTG mutant (Ex2ATG>CTG) and exon 3 AG>AA mutant (Ex3AG>AA) minigenes. The exon combination as verified by sequencing is indicated on the left (products indicated by * are predicted only). Mutation at the exon 3a acceptor site AG>AA abolishes splicing between exon 2 and exon 3b as shown by the absence of exon 2-3b spliced product (lane 2). In2E3a ASO treatment almost completely abrogates exon 2-3a splicing and thus full-length SECISBP2 transcript and dramatically increases exon 2-3b splicing and mtSECISBP2 transcript levels (lane 4). Percentage of exon 3a skipping was calculated from the total value of exon 3a-included and exon 3a-skipped products. (D) Normal human fibroblast cells were treated with In2E3a ASO and levels of SECISBP2 and mtSECISBP2 were measured by real-time RT-PCR. In2E3a-treated cells show a 4-fold increase in mtSECISBP2 and 50% decrease in the full-length SECISBP2 transcript.
###end p 15
###begin p 16
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 64 67 64 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 92 100 92 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 209 212 209 212 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 235 243 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 635 638 635 638 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 506 511 <span type="species:ncbi:9606">human</span>
Schematic representation of human SECISBP2 transcript variants. (A) Genomic organisation of SECISBP2 showing the 17 exons and their sizes in base pairs (bp). Locations of the functional domains are indicated. (B) Alternatively spliced SECISBP2 transcript variants generated through different exon combinations are shown schematically. Arrowheads indicate translation start sites. Designation for the encoded protein isoforms, the corresponding Met start codon number [based on numbering in the full-length human SBP2 sequence (NP_076982)] and predicted molecular weights (MW) of isoforms are indicated to the right of each transcript. (C) An alternative reading frame used for translation of the mitochondrial SBP2 isoform (mtSBP2) initiates in exon 2 (indicated by arrow). The encoded mitochondrial targeting sequence is underlined.
###end p 16
###begin p 17
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 74 77 74 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 297 300 297 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 333 341 333 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 553 556 553 556 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 556 563 556 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 584 592 584 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 630 632 626 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1161 1169 1157 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1231 1241 1227 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1387 1390 1383 1386 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D)</bold>
###xml 1464 1472 1460 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1477 1487 1473 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1570 1580 1566 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1617 1625 1613 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 1398 1403 <span type="species:ncbi:9606">human</span>
SECISBP2 transcript expression and minigene-based in vivo splicing assay. (A) Relative expression levels of full-length and mitochondrial SBP2 transcripts in a cDNA panel of human tissues was analyzed by real-time PCR using transcript specific primers. Data was analyzed using the deltaCT method. (B) Schematic representation of the SECISBP2 minigene indicating exon/intron composition, location of primers used to amplify the minigene-expressed products, annealing site for antisense oligonucleotides (In2E3a ASO) and location of mutations introduced. (C)In vivo splicing pattern of SECISBP2 minigene constructs. RT-PCR of alpha-32P-dCTP labeled products were amplified from C33A cells transfected with wild-type (WT), exon 2 ATG>CTG mutant (Ex2ATG>CTG) and exon 3 AG>AA mutant (Ex3AG>AA) minigenes. The exon combination as verified by sequencing is indicated on the left (products indicated by * are predicted only). Mutation at the exon 3a acceptor site AG>AA abolishes splicing between exon 2 and exon 3b as shown by the absence of exon 2-3b spliced product (lane 2). In2E3a ASO treatment almost completely abrogates exon 2-3a splicing and thus full-length SECISBP2 transcript and dramatically increases exon 2-3b splicing and mtSECISBP2 transcript levels (lane 4). Percentage of exon 3a skipping was calculated from the total value of exon 3a-included and exon 3a-skipped products. (D) Normal human fibroblast cells were treated with In2E3a ASO and levels of SECISBP2 and mtSECISBP2 were measured by real-time RT-PCR. In2E3a-treated cells show a 4-fold increase in mtSECISBP2 and 50% decrease in the full-length SECISBP2 transcript.
###end p 17
###begin title 18
Antisense oligonucleotides
###end title 18
###begin p 19
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
ASOs were synthesized by Dharmacon, Inc. The sequences of the oligonucleotides used are as follows: mG(*)mA(*)mU(*)mC(*)mG(*)mA(*)mU(*)mC(*)mG(*)mA(*)mU(*)mC(*)mG(*)mA(*)mU(*)mC(*)mG(*)mA(*)mU(*)mC(*)mG(*)mA for the control ASO (GATC) and mC*mU*mG*mC*mC*mU*mA*mA*mG*mU*mA*mA*mA*mA*mA*mG*mU*mG*mU*mA*mA*mA*mC for the SBP2 specific ASO spanning the intron 2-exon 3a boundary (In2E3a). In these sequences, the letter m represents an O-methyl modification at the second position of a sugar residue and an asterisk represents a phosphorothioate modification of the backbone.
###end p 19
###begin title 20
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Transfections and in vivo splicing assays
###end title 20
###begin p 21
###xml 1020 1023 1010 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
All reagents were used according to the manufacturer's recommendations. Transient transfections of cells with plasmid DNA or antisense oligonucleotides were performed with Lipofectamine 2000 (Invitrogen). Cells were plated into 6-well plates 24 h prior to transfection so that their density on the day of transfection was 70%. 2.0 mug of plasmid DNA was used per well. For co-transfection experiments, cells were transfected with 1.0 mug of plasmid DNA and 100 nM of ASO per well. Total RNA was isolated 24 h after transfection with Trizol reagent (Invitrogen). To generate cDNA, reverse transcription was carried out with a SuperScript II reaction kit (Invitrogen) using oligo(dT) primer. Generally, 1.0 microg of total RNA was used per 20 microl of reaction mixture. Minigene-specific spliced products were subsequently amplified with forward primer annealing in the vector sequence (P1GFP) 5'-GCTAGCGCATCCGGACTCAGAT-3', and the reverse SBP2-specific primer annealing in exon3b 5'-CTTAAACAGAGCTTTCATTTCTTGTGG-3' using Taq polymerase (Invitrogen). Analysis and quantifications of spliced products were performed with an FPL-5000 Image Reader and ImageGauge software (Fuji Photo Film Inc.) Results were confirmed by three independent experiments.
###end p 21
###begin title 22
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
Expression of endogenous SECISBP2 transcripts
###end title 22
###begin p 23
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 52 62 52 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 359 367 359 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 372 382 372 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 529 537 529 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 577 587 577 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
For analysis of endogenous full-length SECISBP2 and mtSECISBP2, C33A, HeLa and 239T cells were transfected with 100 nM ASOs per well of a 6-well dish. Total RNA was isolated 24 h after transfection with the RNeasy Mini Kit (Qiagen). Reverse transcription was carried out with oligo (dT) primers and SuperScript II (Invitrogen) as described above. Full-length SECISBP2 and mtSECISBP2 transcripts were subsequently amplified by real-time RT-PCR with transcript-specific forward primers 5'-TCCTTATACCCTTGACTCCACA-3' for full-length SECISBP2 and 5'-CCAGTGACAGAAATGTTTACTCAG-3' for mtSECISBP2, and the same reverse primer 5'-TCCTGTCTGTTCGCTTATGG-3'. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard (Fwd 5'-CTGCACACCAACTGCTTAG-3'; Rev 5'-GTCTTCTGGGTGGCAGTGAT-3'). Real-time RT-PCR was performed using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) in a Rotor-Gene 6000 (Corbett Life Science) according to the instructions provided with the kit. Cycling conditions were used as suggested in the SYBR Green kit instructions. Results were analyzed using relative quantification software (Corbett Life Science).
###end p 23
###begin title 24
Cell lysis and western blotting
###end title 24
###begin p 25
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 461 469 461 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 602 610 602 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
Cells were lyzed in universal immunoprecipitation buffer (UIP) as described previously (14). Proteins were separated on 4-12% gradient gels (Invitrogen) unless otherwise stated. Western blotting was performed using the following antibodies: anti-SBP2 and anti-HSP70 antibodies raised in house as described previously (14), anti-actin (Sigma), anti-GFP (Molecular Probes, Invitrogen) and anti-SBP2 antibodies (EC1) (Everest Biotech, Oxfordshire, UK). Except for Figure 4B, images were acquired using an LAS-3000 luminescent image analyzer (Fujifilm Life Science, Stanford, CT, USA). The western blot in Figure 4B was developed using traditional X-ray film.
###end p 25
###begin title 26
Fluorescence microscopy
###end title 26
###begin p 27
###xml 376 381 <span type="species:ncbi:9796">horse</span>
Cells, untransfected or transfected with GFP-tagged proteins, were washed in PBS twice and fixed with 4% paraformaldehyde in PBS for 30 min at room temperature. 4',6'-Diamidino-2-phenylindole (DAPI) was used to stain the nuclei and MitoTracker CMXRos (Molecular Probes, Invitrogen) (50 nM) was used to stain mitochondria. For immunofluorescence, coverslips were blocked in 3% horse serum in PBS, incubated with anti-SBP2 antibody (EC1) at 1 : 250 dilution, followed by incubation with an Alexa fluor 488 dye-conjugated secondary antibody (Molecular Probes, Invitrogen). Colocalization of SBP2 with mitochondria was detected using a double immunofluorescent procedure. Coverslips were mounted with ProLong Gold (Molecular Probes, Invitrogen). Images were acquired in 20 z-sections by using a state-of-the art DeltaVision PD system microscope (Applied Precision, Washington, USA) with a 60x or 100x objective. Images were subsequently deconvolved with 10 cycles of the DeltaVision PD software.
###end p 27
###begin title 28
RESULTS
###end title 28
###begin title 29
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human SBP2 is alternatively spliced
###end title 29
###begin p 30
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 159 167 159 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 365 373 365 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 509 517 509 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 615 623 615 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 747 755 747 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 926 934 914 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1021 1028 1009 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1133 1141 1121 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1154 1162 1142 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1299 1307 1287 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1489 1490 1477 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1491 1493 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1652 1660 1640 1648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1662 1670 1650 1658 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 1698 1706 1686 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1670 1718 1658 1706 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="31">Alternatively spliced human <italic>SECISBP2</italic> transcripts</p>
###xml 1670 1718 1658 1706 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="31">Alternatively spliced human <italic>SECISBP2</italic> transcripts</p></caption>
###xml 1718 1733 1706 1721 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Transcript name</th>
###xml 1733 1749 1721 1737 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Exon combination</th>
###xml 1749 1760 1737 1748 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">No. of ESTs</th>
###xml 1760 1786 1748 1774 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Normal tissue or cell line</th>
###xml 1786 1800 1774 1788 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Primary tumors</th>
###xml 1800 1840 1788 1828 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Cancer derived or transformed cell lines</th>
###xml 1840 1854 1828 1842 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Complete mRNAs</th>
###xml 1718 1854 1706 1842 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><th rowspan="1" colspan="1">Transcript name</th><th rowspan="1" colspan="1">Exon combination</th><th rowspan="1" colspan="1">No. of ESTs</th><th rowspan="1" colspan="1">Normal tissue or cell line</th><th rowspan="1" colspan="1">Primary tumors</th><th rowspan="1" colspan="1">Cancer derived or transformed cell lines</th><th rowspan="1" colspan="1">Complete mRNAs</th></tr>
###xml 1718 1854 1706 1842 <thead xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><th rowspan="1" colspan="1">Transcript name</th><th rowspan="1" colspan="1">Exon combination</th><th rowspan="1" colspan="1">No. of ESTs</th><th rowspan="1" colspan="1">Normal tissue or cell line</th><th rowspan="1" colspan="1">Primary tumors</th><th rowspan="1" colspan="1">Cancer derived or transformed cell lines</th><th rowspan="1" colspan="1">Complete mRNAs</th></tr></thead>
###xml 1854 1862 1842 1850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1854 1862 1842 1850 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>SECISBP2</italic></td>
###xml 1862 1866 1850 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1&#8211;17</td>
###xml 1866 1882 1854 1858 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#8764;120</td>
###xml 1882 1905 1858 1881 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Present in most tissues</td>
###xml 1905 1930 1881 1906 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Present in several tumors</td>
###xml 1930 1959 1906 1935 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Present in several cell lines</td>
###xml 1959 2003 1935 1979 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">NM024077 AK090608 AX746532 BC036109 AF380995</td>
###xml 1854 2003 1842 1979 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>SECISBP2</italic></td><td rowspan="1" colspan="1">1&#8211;17</td><td rowspan="1" colspan="1">&#8764;120</td><td rowspan="1" colspan="1">Present in most tissues</td><td rowspan="1" colspan="1">Present in several tumors</td><td rowspan="1" colspan="1">Present in several cell lines</td><td rowspan="1" colspan="1">NM024077 AK090608 AX746532 BC036109 AF380995</td></tr>
###xml 2003 2013 1979 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 2003 2013 1979 1989 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>mtSECISBP2</italic></td>
###xml 2013 2035 1989 2003 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1,2&#8211;3b,4,5,6 &#8230;</td>
###xml 2035 2037 2003 2005 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">24</td>
###xml 2037 2362 2005 2330 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Pooled glandular (CB956376) Pancreas (BM315064) ES cell lines (CN256608, CN256604, CX870404) T-lympnocytes (CR994587) Liver Cho-CK cell line (CB121625) Thymus (DB160135) Small intestine (DA926236) Fetal brain (DA803510) Thalamus (DA403753) Corpus callosum (DA283160) Testis (DB459197, DC399547) Pooled mixed tissue (CV029893)</td>
###xml 2362 2476 2330 2444 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Retinoblastoma (BE252177) Choriocarcinoma (BG481218) Terratocarcinoma (DA754929, DA758978) Tongue tumor (DA450129)</td>
###xml 2476 2595 2444 2563 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Lymphoma (BQ049808) Osteosarcoma (BG113716) Neuroepithelioma (DA903910) Lymphoma (CR747151) 293T cell line (this study)</td>
###xml 2595 2621 2563 2589 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">AL136881 AK290182 AM392812</td>
###xml 2003 2621 1979 2589 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>mtSECISBP2</italic></td><td rowspan="1" colspan="1">1,2&#8211;3b,4,5,6 &#8230;</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Pooled glandular (CB956376) Pancreas (BM315064) ES cell lines (CN256608, CN256604, CX870404) T-lympnocytes (CR994587) Liver Cho-CK cell line (CB121625) Thymus (DB160135) Small intestine (DA926236) Fetal brain (DA803510) Thalamus (DA403753) Corpus callosum (DA283160) Testis (DB459197, DC399547) Pooled mixed tissue (CV029893)</td><td rowspan="1" colspan="1">Retinoblastoma (BE252177) Choriocarcinoma (BG481218) Terratocarcinoma (DA754929, DA758978) Tongue tumor (DA450129)</td><td rowspan="1" colspan="1">Lymphoma (BQ049808) Osteosarcoma (BG113716) Neuroepithelioma (DA903910) Lymphoma (CR747151) 293T cell line (this study)</td><td rowspan="1" colspan="1">AL136881 AK290182 AM392812</td></tr>
###xml 2621 2629 2589 2597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2621 2636 2589 2600 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;2</td>
###xml 2636 2654 2600 2610 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1&#8211;3a,4,5 &#8230;</td>
###xml 2654 2655 2610 2611 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2</td>
###xml 2655 2678 2611 2634 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">ES cell line (CV811081)</td>
###xml 2678 2678 2634 2634 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2678 2705 2634 2661 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">293T cell line (this study)</td>
###xml 2705 2705 2661 2661 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2621 2705 2589 2661 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;2</td><td rowspan="1" colspan="1">1&#8211;3a,4,5 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">ES cell line (CV811081)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">293T cell line (this study)</td><td rowspan="1" colspan="1"/></tr>
###xml 2705 2713 2661 2669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2705 2720 2661 2672 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;3</td>
###xml 2720 2737 2672 2681 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1,2&#8211;4,5 &#8230;</td>
###xml 2737 2738 2681 2682 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3</td>
###xml 2738 2755 2682 2699 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Testis (DB459197)</td>
###xml 2755 2833 2699 2777 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Genitourinary tract high-grade tumor (AW630547) Mammary gland tumor (BP313796)</td>
###xml 2833 2833 2777 2777 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2833 2833 2777 2777 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2705 2833 2661 2777 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;3</td><td rowspan="1" colspan="1">1,2&#8211;4,5 &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Testis (DB459197)</td><td rowspan="1" colspan="1">Genitourinary tract high-grade tumor (AW630547) Mammary gland tumor (BP313796)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr>
###xml 2833 2841 2777 2785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2833 2849 2777 2789 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;7a</td>
###xml 2849 2868 2789 2800 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1&#8211;5,6b&#8211;7b &#8230;</td>
###xml 2868 2869 2800 2801 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3</td>
###xml 2869 2896 2801 2828 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Uterus (AI129567, AI128470)</td>
###xml 2896 2896 2828 2828 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2896 2896 2828 2828 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2896 2904 2828 2836 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">AB208940</td>
###xml 2833 2904 2777 2836 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;7a</td><td rowspan="1" colspan="1">1&#8211;5,6b&#8211;7b &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Uterus (AI129567, AI128470)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AB208940</td></tr>
###xml 2904 2912 2836 2844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 2904 2915 2836 2847 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>SECISBP2</italic>_7c</td>
###xml 2915 2957 2847 2873 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7c &#8230; (aa TRAD)</td>
###xml 2957 2958 2873 2874 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5</td>
###xml 2958 2991 2874 2907 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">ES cell line (CN256603, CX787609)</td>
###xml 2991 3057 2907 2973 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Squamous cell carcinoma (BP352801) Large cell carcinoma (BQ430224)</td>
###xml 3057 3100 2973 3016 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Ovary terato-carcinoma cell line (BU850141)</td>
###xml 3100 3100 3016 3016 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2904 3100 2836 3016 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_7c</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7c &#8230; (aa TRAD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">ES cell line (CN256603, CX787609)</td><td rowspan="1" colspan="1">Squamous cell carcinoma (BP352801) Large cell carcinoma (BQ430224)</td><td rowspan="1" colspan="1">Ovary terato-carcinoma cell line (BU850141)</td><td rowspan="1" colspan="1"/></tr>
###xml 3100 3104 3016 3020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBP2</italic>
###xml 3100 3108 3016 3024 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>SBP2</italic>_ 7d</td>
###xml 3108 3149 3024 3049 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7d &#8230; (aa TRD)</td>
###xml 3149 3150 3049 3050 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5</td>
###xml 3150 3193 3050 3093 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Pancreas (BU069273) ES cell line (DN602260)</td>
###xml 3193 3228 3093 3128 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Retinoblastoma (BC001189, BE779955)</td>
###xml 3228 3254 3128 3154 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Prostate cancer (EC508545)</td>
###xml 3254 3254 3154 3154 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3100 3254 3016 3154 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>SBP2</italic>_ 7d</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7d &#8230; (aa TRD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreas (BU069273) ES cell line (DN602260)</td><td rowspan="1" colspan="1">Retinoblastoma (BC001189, BE779955)</td><td rowspan="1" colspan="1">Prostate cancer (EC508545)</td><td rowspan="1" colspan="1"/></tr>
###xml 3254 3269 3154 3165 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">SECISBP2_&#916;9</td>
###xml 3269 3293 3165 3173 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#8230; 8&#8211;10 &#8230;</td>
###xml 3293 3294 3173 3174 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2</td>
###xml 3294 3331 3174 3211 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Retinal pigment epithelium (CA389610)</td>
###xml 3331 3356 3211 3236 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Leiomyosarcoma (BU902304)</td>
###xml 3356 3356 3236 3236 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3356 3356 3236 3236 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3254 3356 3154 3236 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">SECISBP2_&#916;9</td><td rowspan="1" colspan="1">&#8230; 8&#8211;10 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Retinal pigment epithelium (CA389610)</td><td rowspan="1" colspan="1">Leiomyosarcoma (BU902304)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr>
###xml 1854 3356 1842 3236 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic></td><td rowspan="1" colspan="1">1&#8211;17</td><td rowspan="1" colspan="1">&#8764;120</td><td rowspan="1" colspan="1">Present in most tissues</td><td rowspan="1" colspan="1">Present in several tumors</td><td rowspan="1" colspan="1">Present in several cell lines</td><td rowspan="1" colspan="1">NM024077 AK090608 AX746532 BC036109 AF380995</td></tr><tr><td rowspan="1" colspan="1"><italic>mtSECISBP2</italic></td><td rowspan="1" colspan="1">1,2&#8211;3b,4,5,6 &#8230;</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Pooled glandular (CB956376) Pancreas (BM315064) ES cell lines (CN256608, CN256604, CX870404) T-lympnocytes (CR994587) Liver Cho-CK cell line (CB121625) Thymus (DB160135) Small intestine (DA926236) Fetal brain (DA803510) Thalamus (DA403753) Corpus callosum (DA283160) Testis (DB459197, DC399547) Pooled mixed tissue (CV029893)</td><td rowspan="1" colspan="1">Retinoblastoma (BE252177) Choriocarcinoma (BG481218) Terratocarcinoma (DA754929, DA758978) Tongue tumor (DA450129)</td><td rowspan="1" colspan="1">Lymphoma (BQ049808) Osteosarcoma (BG113716) Neuroepithelioma (DA903910) Lymphoma (CR747151) 293T cell line (this study)</td><td rowspan="1" colspan="1">AL136881 AK290182 AM392812</td></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;2</td><td rowspan="1" colspan="1">1&#8211;3a,4,5 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">ES cell line (CV811081)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">293T cell line (this study)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;3</td><td rowspan="1" colspan="1">1,2&#8211;4,5 &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Testis (DB459197)</td><td rowspan="1" colspan="1">Genitourinary tract high-grade tumor (AW630547) Mammary gland tumor (BP313796)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;7a</td><td rowspan="1" colspan="1">1&#8211;5,6b&#8211;7b &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Uterus (AI129567, AI128470)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AB208940</td></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_7c</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7c &#8230; (aa TRAD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">ES cell line (CN256603, CX787609)</td><td rowspan="1" colspan="1">Squamous cell carcinoma (BP352801) Large cell carcinoma (BQ430224)</td><td rowspan="1" colspan="1">Ovary terato-carcinoma cell line (BU850141)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SBP2</italic>_ 7d</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7d &#8230; (aa TRD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreas (BU069273) ES cell line (DN602260)</td><td rowspan="1" colspan="1">Retinoblastoma (BC001189, BE779955)</td><td rowspan="1" colspan="1">Prostate cancer (EC508545)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SECISBP2_&#916;9</td><td rowspan="1" colspan="1">&#8230; 8&#8211;10 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Retinal pigment epithelium (CA389610)</td><td rowspan="1" colspan="1">Leiomyosarcoma (BU902304)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody>
###xml 1718 3356 1706 3236 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Transcript name</th><th rowspan="1" colspan="1">Exon combination</th><th rowspan="1" colspan="1">No. of ESTs</th><th rowspan="1" colspan="1">Normal tissue or cell line</th><th rowspan="1" colspan="1">Primary tumors</th><th rowspan="1" colspan="1">Cancer derived or transformed cell lines</th><th rowspan="1" colspan="1">Complete mRNAs</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic></td><td rowspan="1" colspan="1">1&#8211;17</td><td rowspan="1" colspan="1">&#8764;120</td><td rowspan="1" colspan="1">Present in most tissues</td><td rowspan="1" colspan="1">Present in several tumors</td><td rowspan="1" colspan="1">Present in several cell lines</td><td rowspan="1" colspan="1">NM024077 AK090608 AX746532 BC036109 AF380995</td></tr><tr><td rowspan="1" colspan="1"><italic>mtSECISBP2</italic></td><td rowspan="1" colspan="1">1,2&#8211;3b,4,5,6 &#8230;</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Pooled glandular (CB956376) Pancreas (BM315064) ES cell lines (CN256608, CN256604, CX870404) T-lympnocytes (CR994587) Liver Cho-CK cell line (CB121625) Thymus (DB160135) Small intestine (DA926236) Fetal brain (DA803510) Thalamus (DA403753) Corpus callosum (DA283160) Testis (DB459197, DC399547) Pooled mixed tissue (CV029893)</td><td rowspan="1" colspan="1">Retinoblastoma (BE252177) Choriocarcinoma (BG481218) Terratocarcinoma (DA754929, DA758978) Tongue tumor (DA450129)</td><td rowspan="1" colspan="1">Lymphoma (BQ049808) Osteosarcoma (BG113716) Neuroepithelioma (DA903910) Lymphoma (CR747151) 293T cell line (this study)</td><td rowspan="1" colspan="1">AL136881 AK290182 AM392812</td></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;2</td><td rowspan="1" colspan="1">1&#8211;3a,4,5 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">ES cell line (CV811081)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">293T cell line (this study)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;3</td><td rowspan="1" colspan="1">1,2&#8211;4,5 &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Testis (DB459197)</td><td rowspan="1" colspan="1">Genitourinary tract high-grade tumor (AW630547) Mammary gland tumor (BP313796)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;7a</td><td rowspan="1" colspan="1">1&#8211;5,6b&#8211;7b &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Uterus (AI129567, AI128470)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AB208940</td></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_7c</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7c &#8230; (aa TRAD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">ES cell line (CN256603, CX787609)</td><td rowspan="1" colspan="1">Squamous cell carcinoma (BP352801) Large cell carcinoma (BQ430224)</td><td rowspan="1" colspan="1">Ovary terato-carcinoma cell line (BU850141)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SBP2</italic>_ 7d</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7d &#8230; (aa TRD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreas (BU069273) ES cell line (DN602260)</td><td rowspan="1" colspan="1">Retinoblastoma (BC001189, BE779955)</td><td rowspan="1" colspan="1">Prostate cancer (EC508545)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SECISBP2_&#916;9</td><td rowspan="1" colspan="1">&#8230; 8&#8211;10 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Retinal pigment epithelium (CA389610)</td><td rowspan="1" colspan="1">Leiomyosarcoma (BU902304)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table>
###xml 3356 3651 3236 3531 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="32">SECISBP2 transcripts that were identified experimentally or by EST database searches are listed according to the nomenclature proposed in the text. Information on exon combination, number of ESTs present, tissue of origin and corresponding GenBank accession numbers are given. ES=embryonic stem.</p>
###xml 3356 3651 3236 3531 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="32">SECISBP2 transcripts that were identified experimentally or by EST database searches are listed according to the nomenclature proposed in the text. Information on exon combination, number of ESTs present, tissue of origin and corresponding GenBank accession numbers are given. ES=embryonic stem.</p></fn>
###xml 3356 3651 3236 3531 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><fn><p textid="32">SECISBP2 transcripts that were identified experimentally or by EST database searches are listed according to the nomenclature proposed in the text. Information on exon combination, number of ESTs present, tissue of origin and corresponding GenBank accession numbers are given. ES=embryonic stem.</p></fn></table-wrap-foot>
###xml 1662 3651 1650 3531 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="31">Alternatively spliced human <italic>SECISBP2</italic> transcripts</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Transcript name</th><th rowspan="1" colspan="1">Exon combination</th><th rowspan="1" colspan="1">No. of ESTs</th><th rowspan="1" colspan="1">Normal tissue or cell line</th><th rowspan="1" colspan="1">Primary tumors</th><th rowspan="1" colspan="1">Cancer derived or transformed cell lines</th><th rowspan="1" colspan="1">Complete mRNAs</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic></td><td rowspan="1" colspan="1">1&#8211;17</td><td rowspan="1" colspan="1">&#8764;120</td><td rowspan="1" colspan="1">Present in most tissues</td><td rowspan="1" colspan="1">Present in several tumors</td><td rowspan="1" colspan="1">Present in several cell lines</td><td rowspan="1" colspan="1">NM024077 AK090608 AX746532 BC036109 AF380995</td></tr><tr><td rowspan="1" colspan="1"><italic>mtSECISBP2</italic></td><td rowspan="1" colspan="1">1,2&#8211;3b,4,5,6 &#8230;</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Pooled glandular (CB956376) Pancreas (BM315064) ES cell lines (CN256608, CN256604, CX870404) T-lympnocytes (CR994587) Liver Cho-CK cell line (CB121625) Thymus (DB160135) Small intestine (DA926236) Fetal brain (DA803510) Thalamus (DA403753) Corpus callosum (DA283160) Testis (DB459197, DC399547) Pooled mixed tissue (CV029893)</td><td rowspan="1" colspan="1">Retinoblastoma (BE252177) Choriocarcinoma (BG481218) Terratocarcinoma (DA754929, DA758978) Tongue tumor (DA450129)</td><td rowspan="1" colspan="1">Lymphoma (BQ049808) Osteosarcoma (BG113716) Neuroepithelioma (DA903910) Lymphoma (CR747151) 293T cell line (this study)</td><td rowspan="1" colspan="1">AL136881 AK290182 AM392812</td></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;2</td><td rowspan="1" colspan="1">1&#8211;3a,4,5 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">ES cell line (CV811081)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">293T cell line (this study)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;3</td><td rowspan="1" colspan="1">1,2&#8211;4,5 &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Testis (DB459197)</td><td rowspan="1" colspan="1">Genitourinary tract high-grade tumor (AW630547) Mammary gland tumor (BP313796)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_&#916;7a</td><td rowspan="1" colspan="1">1&#8211;5,6b&#8211;7b &#8230;</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Uterus (AI129567, AI128470)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AB208940</td></tr><tr><td rowspan="1" colspan="1"><italic>SECISBP2</italic>_7c</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7c &#8230; (aa TRAD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">ES cell line (CN256603, CX787609)</td><td rowspan="1" colspan="1">Squamous cell carcinoma (BP352801) Large cell carcinoma (BQ430224)</td><td rowspan="1" colspan="1">Ovary terato-carcinoma cell line (BU850141)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>SBP2</italic>_ 7d</td><td rowspan="1" colspan="1">&#8230; 3,4,5, 6a&#8211;7d &#8230; (aa TRD)</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreas (BU069273) ES cell line (DN602260)</td><td rowspan="1" colspan="1">Retinoblastoma (BC001189, BE779955)</td><td rowspan="1" colspan="1">Prostate cancer (EC508545)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SECISBP2_&#916;9</td><td rowspan="1" colspan="1">&#8230; 8&#8211;10 &#8230;</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Retinal pigment epithelium (CA389610)</td><td rowspan="1" colspan="1">Leiomyosarcoma (BU902304)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p textid="32">SECISBP2 transcripts that were identified experimentally or by EST database searches are listed according to the nomenclature proposed in the text. Information on exon combination, number of ESTs present, tissue of origin and corresponding GenBank accession numbers are given. ES=embryonic stem.</p></fn></table-wrap-foot></table-wrap>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 550 556 <span type="species:ncbi:9606">humans</span>
###xml 1127 1132 <span type="species:ncbi:9606">human</span>
###xml 1692 1697 <span type="species:ncbi:9606">human</span>
In humans, the SECISBP2 gene spans a 43 kb region on chromosome 9q22.1 and consists of 17 exons. Following reverse transcription PCR (RT-PCR) of the 5'-end of SECISBP2 using mRNA isolated from 293T cells, we observed a second PCR product, shorter than the full-length transcript (data not shown). Sequence analysis of this band identified two alternatively spliced SECISBP2 variants: one lacking exon 2, and the second lacking part of exon 3, further designated exon 3a. To further examine whether additional SECISBP2 splice variants were present in humans, we searched EST and NR databases using known full-length SECISBP2 sequences and mapped and quantified the identified cDNAs onto the genomic sequence. This search confirmed that full-length SECISBP2 is indeed the most abundant transcript, currently represented by approximately120 ESTs and 5 complete mRNAs, and led to the identification of seven alternatively spliced SECISBP2 variants arising through different exon combinations. These variants are as listed in Table 1 along with their proposed nomenclature. A schematic representation of the genomic organization of human SECISBP2 is shown in Figure 1A, and the spliced variants for which sufficient sequence was available to determine their complete 5'-exon combination are presented in Figure 1B. The three functional domains of SBP2: the RNA binding domain, the Sec insertion domain and the ribosome interacting domain, are located within the C-terminal part of the protein (8,25), which corresponds to exons 12-16. Interestingly, all alternative splicing events occur upstream of exon 11, within the region dispensable for Sec insertion in vitro. Table 1.Alternatively spliced human SECISBP2 transcriptsTranscript nameExon combinationNo. of ESTsNormal tissue or cell linePrimary tumorsCancer derived or transformed cell linesComplete mRNAsSECISBP21-17approximately120Present in most tissuesPresent in several tumorsPresent in several cell linesNM024077 AK090608 AX746532 BC036109 AF380995mtSECISBP21,2-3b,4,5,6 em leader24Pooled glandular (CB956376) Pancreas (BM315064) ES cell lines (CN256608, CN256604, CX870404) T-lympnocytes (CR994587) Liver Cho-CK cell line (CB121625) Thymus (DB160135) Small intestine (DA926236) Fetal brain (DA803510) Thalamus (DA403753) Corpus callosum (DA283160) Testis (DB459197, DC399547) Pooled mixed tissue (CV029893)Retinoblastoma (BE252177) Choriocarcinoma (BG481218) Terratocarcinoma (DA754929, DA758978) Tongue tumor (DA450129)Lymphoma (BQ049808) Osteosarcoma (BG113716) Neuroepithelioma (DA903910) Lymphoma (CR747151) 293T cell line (this study)AL136881 AK290182 AM392812SECISBP2_Delta21-3a,4,5 em leader2ES cell line (CV811081)293T cell line (this study)SECISBP2_Delta31,2-4,5 em leader3Testis (DB459197)Genitourinary tract high-grade tumor (AW630547) Mammary gland tumor (BP313796)SECISBP2_Delta7a1-5,6b-7b em leader3Uterus (AI129567, AI128470)AB208940SECISBP2_7cem leader 3,4,5, 6a-7c em leader (aa TRAD)5ES cell line (CN256603, CX787609)Squamous cell carcinoma (BP352801) Large cell carcinoma (BQ430224)Ovary terato-carcinoma cell line (BU850141)SBP2_ 7dem leader 3,4,5, 6a-7d em leader (aa TRD)5Pancreas (BU069273) ES cell line (DN602260)Retinoblastoma (BC001189, BE779955)Prostate cancer (EC508545)SECISBP2_Delta9em leader 8-10 em leader2Retinal pigment epithelium (CA389610)Leiomyosarcoma (BU902304)SECISBP2 transcripts that were identified experimentally or by EST database searches are listed according to the nomenclature proposed in the text. Information on exon combination, number of ESTs present, tissue of origin and corresponding GenBank accession numbers are given. ES=embryonic stem.
###end p 30
###begin p 31
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 22 27 <span type="species:ncbi:9606">human</span>
Alternatively spliced human SECISBP2 transcripts
###end p 31
###begin p 32
SECISBP2 transcripts that were identified experimentally or by EST database searches are listed according to the nomenclature proposed in the text. Information on exon combination, number of ESTs present, tissue of origin and corresponding GenBank accession numbers are given. ES=embryonic stem.
###end p 32
###begin p 33
###xml 104 112 104 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 251 258 251 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 658 665 658 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 757 765 757 765 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2.</label>
###xml 791 799 791 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 765 819 765 819 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="34">Splice site boundaries of <italic>SECISBP2</italic> transcript variants</p>
###xml 765 819 765 819 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="34">Splice site boundaries of <italic>SECISBP2</italic> transcript variants</p></caption>
###xml 819 819 819 819 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn829i1.jpg"/>
###xml 819 819 819 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><inline-graphic xlink:href="gkn829i1.jpg"/></td>
###xml 819 819 819 819 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><inline-graphic xlink:href="gkn829i1.jpg"/></td></tr>
###xml 819 819 819 819 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1"><inline-graphic xlink:href="gkn829i1.jpg"/></td></tr></tbody>
###xml 819 819 819 819 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><tbody align="left"><tr><td rowspan="1" colspan="1"><inline-graphic xlink:href="gkn829i1.jpg"/></td></tr></tbody></table>
###xml 819 1024 819 1024 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="35">The donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice sites was identified from the genomic DNA sequence (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">http://genome.ucsc.edu</ext-link>) and compared to the consensus of splice site motifs (16). Consensus nucleotides at the 5&#8242; and 3&#8242; splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is shown in italics. *Exons with alternative donor or acceptor sites.</p>
###xml 819 1315 819 1315 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="35">The donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice sites was identified from the genomic DNA sequence (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">http://genome.ucsc.edu</ext-link>) and compared to the consensus of splice site motifs (16). Consensus nucleotides at the 5&#8242; and 3&#8242; splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is shown in italics. *Exons with alternative donor or acceptor sites.</p></fn>
###xml 819 1315 819 1315 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><fn><p textid="35">The donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice sites was identified from the genomic DNA sequence (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">http://genome.ucsc.edu</ext-link>) and compared to the consensus of splice site motifs (16). Consensus nucleotides at the 5&#8242; and 3&#8242; splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is shown in italics. *Exons with alternative donor or acceptor sites.</p></fn></table-wrap-foot>
###xml 757 1315 757 1315 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T2" position="float"><label>Table 2.</label><caption><p textid="34">Splice site boundaries of <italic>SECISBP2</italic> transcript variants</p></caption><table frame="hsides" rules="groups"><tbody align="left"><tr><td rowspan="1" colspan="1"><inline-graphic xlink:href="gkn829i1.jpg"/></td></tr></tbody></table><table-wrap-foot><fn><p textid="35">The donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice sites was identified from the genomic DNA sequence (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">http://genome.ucsc.edu</ext-link>) and compared to the consensus of splice site motifs (16). Consensus nucleotides at the 5&#8242; and 3&#8242; splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is shown in italics. *Exons with alternative donor or acceptor sites.</p></fn></table-wrap-foot></table-wrap>
Sequence analysis of exon/intron boundaries showed that nearly all splice sites within the 5'-region of SECISBP2 conform to consensus sequences (AAG|GU or CAG|GU at the 5'-exon/intron boundary and CAG|G at the 3'-end) (26) with only a few deviations (Table 2). The majority of exons have one donor and one acceptor splice site; however, exons 3 and 7 have multiple acceptor sites, denoted as a, b, c or d. A very complex splicing pattern was noted between exons 6 and 7, with four possible splicing combinations. The most common acceptor site was the 7a site. The 6-7b splice variant appeared to be rare, however, an encoding mRNA derived from brain tissue (Table 1) was present in the EST database. The variants 6-7c and 6-7d were covered by several ESTs. Table 2.Splice site boundaries of SECISBP2 transcript variantsThe donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice sites was identified from the genomic DNA sequence () and compared to the consensus of splice site motifs (16). Consensus nucleotides at the 5' and 3' splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is shown in italics. *Exons with alternative donor or acceptor sites.
###end p 33
###begin p 34
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
Splice site boundaries of SECISBP2 transcript variants
###end p 34
###begin p 35
The donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice sites was identified from the genomic DNA sequence () and compared to the consensus of splice site motifs (16). Consensus nucleotides at the 5' and 3' splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is shown in italics. *Exons with alternative donor or acceptor sites.
###end p 35
###begin p 36
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 236 244 236 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 311 319 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 398 405 398 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 602 609 602 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 685 693 685 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
All SECISBP2 transcripts for which sufficient 5'-sequence information was available appear to begin with exon 1. This suggests the usage of a common promoter, located upstream of exon 1. As mentioned above, the overwhelming majority of SECISBP2 transcripts include all exons. However, the alternatively spliced SECISBP2 variants seem to be expressed in normal as well as in cancer-derived tissues (Table 1). The best represented alternatively spliced transcript lacked exon 3a as evidenced by 24 ESTs from normal and cancer-derived tissues and cell lines, and was also covered by three complete mRNAs (Table 1). Despite the presence of a large number of ESTs covering the 5'-region of SECISBP2 sequence, no alternative splicing events were detected downstream of exon 10.
###end p 36
###begin title 37
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
Alternative splicing of SECISBP2 creates several open reading frames
###end title 37
###begin p 38
###xml 233 241 233 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 536 544 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 826 836 818 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 841 851 833 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2E6</italic>
###xml 996 1004 988 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1422 1430 1414 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1921 1924 1913 1916 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">294</sup>
###xml 1962 1965 1954 1957 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 1965 1966 1957 1958 <monospace xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</monospace>
###xml 2076 2091 2068 2079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2_&#916;9</italic>
We next examined the nucleotide sequences of the various transcripts for their potential to encode complete open reading frames (ORFs), and found that five SBP2 isoforms initiating from five different ATG start sites can be encoded (Figure 1C). As previously shown, the full-length SBP2 is translated using the first ATG codon in exon 1. This main ORF is however abrogated for some of the variants as premature termination codons (PTCs) are generated, suggesting a possibility of the use of alternative ATG start sites. As indicated in Figure 1B, these potential alternative translation initiation sites (referred by amino acid numbering in full-length SBP2) are methionine (Met) 69 within exon 3a for SBP2_Delta2, and Met 233 within exon 5 for SBP2_Delta3 and they are in the same frame as full-length SBP2. However, for the mtSECISBP2 and SECISBP2E6 transcripts, the first ATG codon downstream of the PTC is created in a different frame in exon 2 (Met 33) and in exon 6 (Met 283) respectively (Figure 1B). These reading frames create a short N-terminal amino acid composition different to full-length SBP2 (i.e., 27 aa for mtSBP2 MVRVLRSMCLPQLCSHILSVCSGTTSDR, and 11 aa for SBP2E6 MPLPILLHVQE), however, these reconnect with the full-length SBP2 reading frame at the next splice site. Interestingly, motif analysis using the PSORTII program predicted the existence of a classical MTS within the exon 3a-deleted variant (Figure 1C), and this form is further designated as mitochondrial SBP2, mtSBP2. The alternate reading frame for SBP2E6 did not seem to encode any targeting signals or motifs different to full-length SBP2. The complex splicing pattern between exon 6 and 7 was interesting as all splicing variations lead to changes in the amino acid composition of the encoded proteins. The splicing from exon 6-7c and 6-7d lead to deletion of a stretch of 38 or 39 amino acids (aa 294-331 or aa 294-332) from exon 7 (294ELSWTPMGYVVRQTLSTELSAAPKNVTSMINLKTIASS331), however, the reading frame starting in exon 1 is maintained throughout both isoforms. The ESTs covering the SECISBP2_Delta9 transcript did not have sufficient sequence upstream of the splicing event in order to determine its translation initiation sites; however, ORF prediction indicated that the reading frame in exon 1 can be maintained despite exon 9 skipping.
###end p 38
###begin title 39
Evolutionary aspects of splicing events within SBP2
###end title 39
###begin p 40
###xml 126 134 126 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 202 210 202 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 416 421 416 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27 B28 B29">27&#8211;29</xref>
###xml 530 538 530 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 695 703 695 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 899 907 899 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1145 1153 1145 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1418 1428 1418 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 893 898 <span type="species:ncbi:9606">human</span>
###xml 981 987 <span type="species:ncbi:9606">humans</span>
###xml 1139 1144 <span type="species:ncbi:9606">human</span>
###xml 1217 1224 <span type="species:ncbi:9031">chicken</span>
###xml 1226 1231 <span type="species:ncbi:9940">sheep</span>
###xml 1233 1236 <span type="species:ncbi:9823">pig</span>
###xml 1238 1241 <span type="species:ncbi:9913">cow</span>
###xml 1264 1269 <span type="species:ncbi:10090">mouse</span>
###xml 1271 1274 <span type="species:ncbi:10116">rat</span>
###xml 1279 1282 <span type="species:ncbi:9615">dog</span>
###xml 1543 1548 <span type="species:ncbi:9606">human</span>
###xml 1557 1564 <span type="species:ncbi:9031">chicken</span>
###xml 1635 1641 <span type="species:ncbi:9606">humans</span>
We next investigated the extent of alternative splicing events in SBP2 in other species. We thus analyzed the distribution of SECISBP2 homologs, the conservation of splicing events and evolution of the SECISBP2 gene in genomic and EST databases. As recently established, selenoprotein genes are widely distributed among eukaryotes including all vertebrates and most arthropods, nematodes, protozoa and lower plants (27-29). Selenoproteins were lost in fungi, land plants, some insects and most eukaryotic parasites. We found that SECISBP2 homologs are present in all selenoprotein-containing genomes, and absent in EST and genomic databases of organisms lacking Sec utilization, suggesting that SECISBP2 co-evolved with the eukaryotic Sec-decoding trait. Several alternatively spliced transcripts were found in EST and genomic databases of different organisms, some of which were identical to human SECISBP2. Because the mtSBP2 is the most common isoform after full-length SBP2 in humans, we were particularly interested in its evolutionary conservation and existence in other species. Interestingly, sequence comparison between exon 2 of human SECISBP2 and other homologs revealed that the ATG codon is conserved in chicken, sheep, pig, cow and monkey but not in mouse, rat and dog where it is present as GTG or CTG, which are possible weak translation initiation codons. However, we did not detect ESTs representing mtSECISBP2 in other organisms except for a distant homolog containing a strong predicted MTS (but low sequence similarity to human MTS) in chicken. It thus appears that the predicted mtSBP2 isoform may be specific to humans.
###end p 40
###begin title 41
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Characterization of SBP2 splicing in vivo and modulation with antisense oligonucleotides
###end title 41
###begin p 42
###xml 73 81 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 210 220 210 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 579 587 579 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 620 630 620 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 644 652 644 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 655 663 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 668 678 668 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 806 814 806 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 819 829 819 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 945 952 933 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1040 1050 1016 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1092 1100 1068 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1155 1165 1131 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 478 483 <span type="species:ncbi:9606">human</span>
The identification of alternative splicing within the 5'-region of human SECISBP2 prompted us to further characterize and quantify the occurrence of these events in vivo. We were particularly interested in the mtSECISBP2 variant since it appeared to be the best represented transcript after the full-length transcript. To gain a better insight into the expression pattern of the two transcripts, we first quantified their relative expression levels in a cDNA panel from various human tissues by real-time RT-PCR using isoform-specific primers spanning the exon 2-3a boundary for SECISBP2, and the exon 2-3b boundary for mtSECISBP2. As shown in Figure 2A, SECISBP2 and mtSECISBP2 were expressed in all tissues tested, with the highest expression levels for both transcripts in testis. The ratio between the SECISBP2 and mtSECISBP2 was on average approximately4.4 : 1 in most tissues, which is consistent with the bioinformatics data presented in Table 1. However, colon, thymus and leucocytes had a approximately2 : 1 ratio, indicating that mtSECISBP2 is most abundantly expressed relative to SECISBP2 in these tissues. We also confirmed the expression of mtSECISBP2 variant in a number of normal and cancer-derived cell lines including ones used in this study (data not shown).
###end p 42
###begin p 43
###xml 62 70 62 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 104 112 104 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 174 182 174 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 297 300 297 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">359</sup>
###xml 413 423 409 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 477 479 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99</sup>
###xml 708 716 704 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 729 731 721 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 825 833 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 856 864 848 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 940 950 932 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 955 963 947 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1001 1011 989 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1051 1059 1039 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1263 1271 1251 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1448 1458 1436 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1570 1578 1558 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
As a second approach to characterize and potentially modulate SECISBP2 splicing in vivo, we generated a SECISBP2 minigene construct (WT minigene), schematically presented in Figure 2B. We also generated two mutant minigene constructs: one harbouring a point mutation at the exon 3a 3' splice site 359AG>AA (named Ex3AG>AADeltaT) which should abrogate the splicing at this site and hence deplete the production of mtSECISBP2; and a second construct harbouring a point mutation (99ATG>CTG) to abrogate mtSBP2 start codon in exon 2 (named Ex2ATG>CTG). The minigenes were transfected into C33A cells and products were analyzed by RT-PCR using primers specific to the minigene-derived transcripts as indicated in Figure 2B. The alpha-32P-dCTP labeled products were separated by native PAGE and verified by sequencing. As shown in Figure 2C, lane 1, full-length SECISBP2 was the predominant transcript expressed from the WT minigene, followed by mtSECISBP2 and SECISBP2_Delta2. These results confirmed that mtSECISBP2 may indeed be the second most abundant SECISBP2 transcript. Notably, the Ex3AG>AA mutation indeed abrogated the exon 3a 3' splice site responsible for the skipping of exon 3a, which is clearly evident by the absence of the mtSBP2 encoding transcript (Figure 2C, lane 2). This observation also conclusively confirmed the existence of an alternative acceptor site within exon 3, and shows that this site is required for production of the mtSECISBP2 transcript. As expected, the ATG mutant minigene showed no difference in splicing compared to the WT minigene (Figure 2C, lane 3).
###end p 43
###begin p 44
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 416 426 416 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 879 887 879 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1110 1120 1110 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1370 1378 1370 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1721 1729 1721 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">figure 2</xref>
###xml 1862 1869 1862 1869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1937 1945 1937 1945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1655 1660 <span type="species:ncbi:9606">human</span>
ASO with a 2'-O-methyl modified ribonucleotide with phosphorothioate backbone have been used to manipulate pre-mRNA splicing in the spinal muscular atrophy gene, SMN2 (30). This backbone modification imparts a very high affinity for targeted mRNA, resistance to both exo- and endonucleases and does not support cleavage of hybridized mRNA by RNAse H (31). We employed this technology to test whether splicing of the mtSECISBP2 can be enhanced using a 23-mer ASO complementary to the last 19 nt of intron 2 and the first four nucleotides of exon 3a (named In2E3a). This was expected to promote exon 3a skipping and thus block splicing of the full-length transcript and enhance the production of the mtSBP2-encoding transcript. An unrelated ASO was used as control. Resulting PCR products from cells co-transfected with the In2E3a, or control ASO, and the WT minigene are shown in Figure 2C, lanes 4 and 5. Notably, the In2E3a ASO efficiently blocked splicing at the exon 3a site, thus, promoting exon 3a skipping as shown by a dramatic reduction in full-length transcript levels and a corresponding increase in mtSECISBP2 transcript (lane 4), while the control ASO had no effect on the splicing pattern (lane 5 compared to lane 1). Similar results were obtained in HeLa cells (data not shown). The In2E3a ASO was also efficient in altering the splicing of the endogenous SECISBP2 transcript in several cell lines, as measured by real-time RT-PCR with isoform-specific primers. Generally, a 2- to 4-fold increase in exon 3a skipping with a corresponding 50-60% decrease in exon 3a inclusion was obtained in cell lines including C33A, HeLa and untransformed human fibroblast cells (NFF). Results from NFF cells are shown in figure 2D. Taken together, these findings demonstrated that the In2E3a ASO can be used as an efficient tool to promote SBP2 exon 3a skipping in vivo, and to generate predominantly the mtSBP2-encoding transcript from SECISBP2 gene.
###end p 44
###begin title 45
Several SBP2 isoforms are expressed from the minigene
###end title 45
###begin p 46
###xml 682 690 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 883 891 883 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1218 1221 1218 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">367</sup>
###xml 1487 1495 1483 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1537 1544 1533 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1628 1636 1624 1632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 1817 1826 1813 1822 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 1870 1873 1866 1869 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 1916 1924 1912 1920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2381 2384 2377 2380 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 2524 2534 2520 2530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1826 2637 1822 2633 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="47">Minigene-based expression of SBP2 isoforms. <bold>(A)</bold> The minigenes (described in the legend to <xref ref-type="fig" rid="F2">Figure 2</xref>) were transfected into 293T cells and the proteins expressed were separated on 4&#8211;12% gradient gels and analyzed by western blotting with anti-GFP and anti-SBP2 antibodies. Western blots with the two antibodies show similar staining pattern and thus confirm the expression of several SBP2 isoforms initiating from alternative ATG codons. E3aSBP2-GFP, E3bSBP2-GFP and E5SBP2-GFP refer to isoforms initiating at ATG codons in exons 3a, 3b and 5 respectively. <bold>(B)</bold> Western blots of cells co-transfected with wild-type (WT) minigene and the In2E3a antisense oligonucleotides that promotes splicing of the <italic>mtSECISBP2</italic> transcript show translation of the mtSBP2GFP isoform. Actin was used as a control for protein loading.</p>
###xml 1826 2637 1822 2633 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="47">Minigene-based expression of SBP2 isoforms. <bold>(A)</bold> The minigenes (described in the legend to <xref ref-type="fig" rid="F2">Figure 2</xref>) were transfected into 293T cells and the proteins expressed were separated on 4&#8211;12% gradient gels and analyzed by western blotting with anti-GFP and anti-SBP2 antibodies. Western blots with the two antibodies show similar staining pattern and thus confirm the expression of several SBP2 isoforms initiating from alternative ATG codons. E3aSBP2-GFP, E3bSBP2-GFP and E5SBP2-GFP refer to isoforms initiating at ATG codons in exons 3a, 3b and 5 respectively. <bold>(B)</bold> Western blots of cells co-transfected with wild-type (WT) minigene and the In2E3a antisense oligonucleotides that promotes splicing of the <italic>mtSECISBP2</italic> transcript show translation of the mtSBP2GFP isoform. Actin was used as a control for protein loading.</p></caption>
###xml 2637 2637 2633 2633 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn829f3"/>
###xml 1817 2637 1813 2633 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="47">Minigene-based expression of SBP2 isoforms. <bold>(A)</bold> The minigenes (described in the legend to <xref ref-type="fig" rid="F2">Figure 2</xref>) were transfected into 293T cells and the proteins expressed were separated on 4&#8211;12% gradient gels and analyzed by western blotting with anti-GFP and anti-SBP2 antibodies. Western blots with the two antibodies show similar staining pattern and thus confirm the expression of several SBP2 isoforms initiating from alternative ATG codons. E3aSBP2-GFP, E3bSBP2-GFP and E5SBP2-GFP refer to isoforms initiating at ATG codons in exons 3a, 3b and 5 respectively. <bold>(B)</bold> Western blots of cells co-transfected with wild-type (WT) minigene and the In2E3a antisense oligonucleotides that promotes splicing of the <italic>mtSECISBP2</italic> transcript show translation of the mtSBP2GFP isoform. Actin was used as a control for protein loading.</p></caption><graphic xlink:href="gkn829f3"/></fig>
###xml 2637 2646 2633 2642 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 2739 2742 2735 2738 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 3078 3081 3074 3077 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 3379 3387 3367 3375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 3389 3392 3377 3380 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 2646 3960 2642 3948 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="48">Localization of over-expressed mtSBP2-GFP and endogenous mtSBP2 isoform at the mitochondria. <bold>(A)</bold> The localization of GFP-tagged full-length (FLSBP2-GFP) and mitochondrial SBP2 isoforms (mtSBP2-GFP) in C33A cells was visualized by fluorescence microscopy. Mitochondria were stained with MitoTracker Red CMX-Ros. Single Z-layer deconvolution images show strong mitochondrial localization of mtSBP2-GFP (yellow) but not of FLSBP2-GFP. <bold>(B)</bold> Western blot of SBP2 isoforms expressed from cDNAs as GFP-fusion proteins. SBP2_&#916;2-GFP and SBP2_&#916;3a-GFP lack exons 2 and 3a respectively. mtSBP2-GFP cDNA begins at the ATG in exon 2. These proteins were resolved on a 6% SDS&#8211;PAGE gel, which yielded a higher level of separation compared to <xref ref-type="fig" rid="F3">Figure 3</xref>. <bold>(C)</bold> High resolution single Z-layer deconvolution images show the localization of mtSBP2-GFP and endogenous mtSBP2 proteins at the mitochondria in C33A cells. 10% of cells display strong mitochondrial staining as shown by the yellow staining in the top panel enlargement, while in most cells only a few dots were detected within the mitochondria (middle panel). Immunofluorescence staining was performed with the anti-SBP2 antibody EC1. Enlargements show a similar punctated staining pattern along the mitochondria for both mtSBP2-GFP (bottom panel) and endogenous mtSBP2.</p>
###xml 2646 3960 2642 3948 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="48">Localization of over-expressed mtSBP2-GFP and endogenous mtSBP2 isoform at the mitochondria. <bold>(A)</bold> The localization of GFP-tagged full-length (FLSBP2-GFP) and mitochondrial SBP2 isoforms (mtSBP2-GFP) in C33A cells was visualized by fluorescence microscopy. Mitochondria were stained with MitoTracker Red CMX-Ros. Single Z-layer deconvolution images show strong mitochondrial localization of mtSBP2-GFP (yellow) but not of FLSBP2-GFP. <bold>(B)</bold> Western blot of SBP2 isoforms expressed from cDNAs as GFP-fusion proteins. SBP2_&#916;2-GFP and SBP2_&#916;3a-GFP lack exons 2 and 3a respectively. mtSBP2-GFP cDNA begins at the ATG in exon 2. These proteins were resolved on a 6% SDS&#8211;PAGE gel, which yielded a higher level of separation compared to <xref ref-type="fig" rid="F3">Figure 3</xref>. <bold>(C)</bold> High resolution single Z-layer deconvolution images show the localization of mtSBP2-GFP and endogenous mtSBP2 proteins at the mitochondria in C33A cells. 10% of cells display strong mitochondrial staining as shown by the yellow staining in the top panel enlargement, while in most cells only a few dots were detected within the mitochondria (middle panel). Immunofluorescence staining was performed with the anti-SBP2 antibody EC1. Enlargements show a similar punctated staining pattern along the mitochondria for both mtSBP2-GFP (bottom panel) and endogenous mtSBP2.</p></caption>
###xml 3960 3960 3948 3948 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn829f4"/>
###xml 2637 3960 2633 3948 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="48">Localization of over-expressed mtSBP2-GFP and endogenous mtSBP2 isoform at the mitochondria. <bold>(A)</bold> The localization of GFP-tagged full-length (FLSBP2-GFP) and mitochondrial SBP2 isoforms (mtSBP2-GFP) in C33A cells was visualized by fluorescence microscopy. Mitochondria were stained with MitoTracker Red CMX-Ros. Single Z-layer deconvolution images show strong mitochondrial localization of mtSBP2-GFP (yellow) but not of FLSBP2-GFP. <bold>(B)</bold> Western blot of SBP2 isoforms expressed from cDNAs as GFP-fusion proteins. SBP2_&#916;2-GFP and SBP2_&#916;3a-GFP lack exons 2 and 3a respectively. mtSBP2-GFP cDNA begins at the ATG in exon 2. These proteins were resolved on a 6% SDS&#8211;PAGE gel, which yielded a higher level of separation compared to <xref ref-type="fig" rid="F3">Figure 3</xref>. <bold>(C)</bold> High resolution single Z-layer deconvolution images show the localization of mtSBP2-GFP and endogenous mtSBP2 proteins at the mitochondria in C33A cells. 10% of cells display strong mitochondrial staining as shown by the yellow staining in the top panel enlargement, while in most cells only a few dots were detected within the mitochondria (middle panel). Immunofluorescence staining was performed with the anti-SBP2 antibody EC1. Enlargements show a similar punctated staining pattern along the mitochondria for both mtSBP2-GFP (bottom panel) and endogenous mtSBP2.</p></caption><graphic xlink:href="gkn829f4"/></fig>
We next investigated the translation pattern of the alternatively spliced SBP2 isoforms using the minigene constructs. These were transiently transfected in several cell lines including 293T, C33A and HeLa, and the expressed proteins were analyzed by western blotting. Blots were probed with anti-GFP antibodies (which is tagged at the C-terminus of SBP2), and with anti-SBP2 antibodies raised against a central region of SBP2 (exon 6-8) to ensure that the proteins detected are products that initiate at different ATG codons within the N-terminal region of SBP2 rather than degradation products. A representative example of the minigenes' expression pattern in 293T cells is shown Figure 3A. Consistent with the data obtained from the splicing assay, full-length SBP2 initiating from the ATG in exon 1, was by far the highest expressed protein from the WT and Ex2ATG>CTG minigenes (Figure 3A lanes 1 and 2), however, the presence of multiple bands detected by both antibodies suggested that proteins initiating from other ATG start codons are expressed. Due to the small differences in their size (85.9 kDa, 86 kDa, 80 kDa) some of them could not be resolved and identified easily. However, the nucleotide deletion (T367) in exon 3b of the Ex3AG >AADeltaT minigene which abrogates the ORFs starting at ATG codons in exons 1, 2 or 3a by creating PTCs, enabled us to identify two of the additional bands as the SBP2 isoforms initiating in exon 3b from Met 139 and in exon 5 from Met 233 (Figure 3A lane 4). Thus, using the minigene-based in vivo splicing assay we have been able to convincingly show that alternative splicing of SECISBP2 may have a functional relevance as multiple SBP2 isoforms initiating from different ATG start codons and containing different N-termini amino acid composition are being expressed. Figure 3.Minigene-based expression of SBP2 isoforms. (A) The minigenes (described in the legend to Figure 2) were transfected into 293T cells and the proteins expressed were separated on 4-12% gradient gels and analyzed by western blotting with anti-GFP and anti-SBP2 antibodies. Western blots with the two antibodies show similar staining pattern and thus confirm the expression of several SBP2 isoforms initiating from alternative ATG codons. E3aSBP2-GFP, E3bSBP2-GFP and E5SBP2-GFP refer to isoforms initiating at ATG codons in exons 3a, 3b and 5 respectively. (B) Western blots of cells co-transfected with wild-type (WT) minigene and the In2E3a antisense oligonucleotides that promotes splicing of the mtSECISBP2 transcript show translation of the mtSBP2GFP isoform. Actin was used as a control for protein loading.Figure 4.Localization of over-expressed mtSBP2-GFP and endogenous mtSBP2 isoform at the mitochondria. (A) The localization of GFP-tagged full-length (FLSBP2-GFP) and mitochondrial SBP2 isoforms (mtSBP2-GFP) in C33A cells was visualized by fluorescence microscopy. Mitochondria were stained with MitoTracker Red CMX-Ros. Single Z-layer deconvolution images show strong mitochondrial localization of mtSBP2-GFP (yellow) but not of FLSBP2-GFP. (B) Western blot of SBP2 isoforms expressed from cDNAs as GFP-fusion proteins. SBP2_Delta2-GFP and SBP2_Delta3a-GFP lack exons 2 and 3a respectively. mtSBP2-GFP cDNA begins at the ATG in exon 2. These proteins were resolved on a 6% SDS-PAGE gel, which yielded a higher level of separation compared to Figure 3. (C) High resolution single Z-layer deconvolution images show the localization of mtSBP2-GFP and endogenous mtSBP2 proteins at the mitochondria in C33A cells. 10% of cells display strong mitochondrial staining as shown by the yellow staining in the top panel enlargement, while in most cells only a few dots were detected within the mitochondria (middle panel). Immunofluorescence staining was performed with the anti-SBP2 antibody EC1. Enlargements show a similar punctated staining pattern along the mitochondria for both mtSBP2-GFP (bottom panel) and endogenous mtSBP2.
###end p 46
###begin p 47
###xml 44 47 44 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 90 98 90 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 555 558 555 558 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 698 708 698 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
Minigene-based expression of SBP2 isoforms. (A) The minigenes (described in the legend to Figure 2) were transfected into 293T cells and the proteins expressed were separated on 4-12% gradient gels and analyzed by western blotting with anti-GFP and anti-SBP2 antibodies. Western blots with the two antibodies show similar staining pattern and thus confirm the expression of several SBP2 isoforms initiating from alternative ATG codons. E3aSBP2-GFP, E3bSBP2-GFP and E5SBP2-GFP refer to isoforms initiating at ATG codons in exons 3a, 3b and 5 respectively. (B) Western blots of cells co-transfected with wild-type (WT) minigene and the In2E3a antisense oligonucleotides that promotes splicing of the mtSECISBP2 transcript show translation of the mtSBP2GFP isoform. Actin was used as a control for protein loading.
###end p 47
###begin p 48
###xml 93 96 93 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 432 435 432 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 733 741 725 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 743 746 735 738 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
Localization of over-expressed mtSBP2-GFP and endogenous mtSBP2 isoform at the mitochondria. (A) The localization of GFP-tagged full-length (FLSBP2-GFP) and mitochondrial SBP2 isoforms (mtSBP2-GFP) in C33A cells was visualized by fluorescence microscopy. Mitochondria were stained with MitoTracker Red CMX-Ros. Single Z-layer deconvolution images show strong mitochondrial localization of mtSBP2-GFP (yellow) but not of FLSBP2-GFP. (B) Western blot of SBP2 isoforms expressed from cDNAs as GFP-fusion proteins. SBP2_Delta2-GFP and SBP2_Delta3a-GFP lack exons 2 and 3a respectively. mtSBP2-GFP cDNA begins at the ATG in exon 2. These proteins were resolved on a 6% SDS-PAGE gel, which yielded a higher level of separation compared to Figure 3. (C) High resolution single Z-layer deconvolution images show the localization of mtSBP2-GFP and endogenous mtSBP2 proteins at the mitochondria in C33A cells. 10% of cells display strong mitochondrial staining as shown by the yellow staining in the top panel enlargement, while in most cells only a few dots were detected within the mitochondria (middle panel). Immunofluorescence staining was performed with the anti-SBP2 antibody EC1. Enlargements show a similar punctated staining pattern along the mitochondria for both mtSBP2-GFP (bottom panel) and endogenous mtSBP2.
###end p 48
###begin p 49
###xml 135 143 135 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 264 272 264 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 919 927 919 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1216 1224 1212 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
Intriguingly, we could not detect a decrease in a band representing the mtSBP2 protein expressed from the Ex2ATG>CTG mutant construct (Figure 3A lane 2). On the contrary, a small increase in expression of the band below the full-length SBP2 was consistently seen (Figure 3A lane 2). According to molecular weight prediction, this band could represent a protein initiating from ATG codons in exon 3a or exon 3b. We speculate that the increased expression of this band in the Ex2ATG>CTG mutant could be the consequence of lack of translation initiation in exon 2 due to abrogation of the ATG codon with a consequent promotion of translation from downstream ATG codons. Although we could not detect the mtSBP2 isoform expressed from the minigene by western blotting, its expression levels could be below the detection limit, but still responsible for regulating the expression of other downstream ATG-initiating isoforms (Figure 3A lane 1 compared to lane 2). However, this possibility remains to be investigated. We also noted that translation of the SBP2E3b isoform from the Ex3AG>AADeltaT minigene did not increase significantly when a point mutation that abrogates the full-length SBP2 reading frame is introduced (Figure 3A lane 4). This suggests that the ATG codon context in exon 3b is rather weak, or that expression of this isoform is strictly regulated. The overall SBP2 splicing pattern was similar in other cell lines tested despite variations in transfection efficiency (data not shown).
###end p 49
###begin p 50
###xml 17 25 17 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 103 113 103 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 300 308 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 519 526 519 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 631 641 631 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 841 849 841 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
We showed above (Figure 2B) that the In2E3a ASO is extremely efficient at increasing the levels of the mtSECISBP2 transcript both off the minigene and endogenously. We therefore tested if co-transfecting the WT minigene with the In2E3A ASO could induce the expression of the mtSBP2 protein. As shown Figure 3B, a band that corresponds to the predicted size of mtSBP2-GFP was indeed apparent in In2E3a ASO co-transfected cells, but not in control ASO transfected cells, demonstrating that this isoform can be translated in vivo, albeit very inefficiently. Although the In2E3a ASO proved efficient at inducing splicing of endogenous mtSECISBP2 transcript, we were unable to detect the endogenous mtSBP2 protein following In2E3a ASO transfection, despite extensive attempts in several cell lines. Overall, these results showed that full-length SECISBP2 is the most abundant and preferentially translated SBP2-encoding transcript. However, the alternatively spliced transcripts generated are also translated into protein, albeit far less efficiently.
###end p 50
###begin title 51
The mtSBP2 isoform localizes to mitochondria
###end title 51
###begin p 52
###xml 151 159 151 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 236 246 236 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 1126 1134 1122 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1323 1331 1319 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1516 1518 1512 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1519 1521 1515 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1992 2000 1972 1980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 2290 2298 2270 2278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 2677 2685 2653 2661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 2818 2826 2790 2798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
One of the main aims of the minigene splicing assay was to analyze the expression and localization of the protein encoded by the most common alternate SECISBP2 transcript-mtSBP2. Although the assay convincingly showed expression of the mtSECISBP2 transcript, it proved less amenable at analyzing the protein expression. Thus, in order to determine if the predicted mtSBP2 does indeed localize to mitochondria, we expressed the mtSBP2-encoding cDNA (commencing at the ATG codon in exon 2) fused N-terminal to GFP (mtSBP2-GFP) in C33A cells, and analyzed its subcellular localization by co-staining with the mitochondrial marker MitoTracker Red CMX-Ros. The full-length FLSBP2-GFP construct and a construct lacking the putative MTS encoded by the alternate reading frame in exon 2 (SBP2_Delta2-GFP) were used for comparison. Localization of the proteins was visualized using a Z-scanning microscope followed by image deconvolution. Interestingly, mtSBP2-GFP expressing cells exhibited distinct cytoplasmic fluorescence, which overlapped significantly with the MitoTracker staining as indicated by the intense yellow staining in Figure 4A (Pearson coefficient 0.879). FLSBP2-GFP protein displayed a strong peri-nuclear punctate staining, however, this fluorescence did not overlap significantly with the MitoTracker staining (Figure 4A bottom panels, Pearson coefficient 0.264). Most likely, this pattern represents a ribosomal/endoplasmic reticulum (ER) staining which is the believed functional localization of SBP2 (14,32). Similar to FLSBP2-GFP, SBP2_Delta2-GFP localized throughout the cytoplasm and showed marginal co-localization with MitoTracker (data not shown). This data established that the MTS encoded by the alternative reading frame in exon 2 is functional, and required for targeting the mtSBP2-GFP protein to the mitochondria. It should be noted that only approximately10% of cells transfected with the mtSBP2-GFP plasmid displayed strong mitochondrial localization as shown in Figure 4A, and some of the transfected cells also displayed a diffuse cytoplasmic fluorescence that did not co-localize with the MitoTracker staining (data not shown). Indeed, western blot of mtSBP2-GFP transfected cells showed the presence of additional proteins initiating in exon 3b and exon 5 (Figure 4B, lane 4), which explained the cytoplasmic fluorescence observed. Notably, mtSBP2-GFP was poorly expressed in comparison to other isoforms and we consistently observed this in several cell lines tested. It is also interesting to note that cells transfected with a construct that lacks exon 2 (SBP2_Delta2-GFP) expressed high levels of proteins initiating in exons 3a, 3b and 5 (Figure 4B, lane 4), while lack of exon 3a (SBP2_Delta3a-GFP) did not seem to have a similar effect on proteins initiating in exons 3b and 5 (Figure 4B, lane 3). These results suggest that exon 2 might play a role in regulating the expression of some of the SBP2 isoforms by suppressing translation initiation at ATG start sites in exons 3a, 3b and 5. These results are also in agreement with the results from the minigene assay where mutation to the exon 2 ATG start site led to increased translation from exon 3b.
###end p 52
###begin p 53
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 973 981 973 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1212 1220 1200 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1332 1340 1320 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
We also sought to determine whether the mtSBP2 isoform, or additional spliced variants could be detected endogenously in cells using our previously described anti-SBP2 antibody raised against an epitope in exons 6-8 (aa 279-378 in SBP2) (14) which should detect most isoforms, if expressed. However, we were unable to detect any SBP2 isoforms other than the full-length SBP2 by western blotting. Similarly, analysis of mitochondrial fractions of cells failed to reveal the existence of mtSBP2 by western blotting and this antibody was not suitable for immunofluorescence-based detection of mtSBP2 due to similar level of staining in SBP2-depleted and normal cells. Notably, a new anti-peptide antibody raised against the C-terminus of SBP2 (referred to as anti-SBP2 EC1) was shown to be very specific for SBP2 (data not shown). We used this antibody in immunofluorescence of C33A cells and found that the majority of cells showed a distinct punctated cytoplasmic staining (Figure 4C, middle panel). Interestingly, while most cells also showed some punctated staining along the mitochodria, approximately5-10% of cells displayed a clear mitochondrial SBP2 staining that co-localized strongly with MitoTracker in (Figure 4C, top panel and enlargement). This staining pattern was similar to that observed for overexpressed mtSBP2-GFP (Figure 4C, bottom panel and enlargement). Collectively, these results provide evidence that mtSBP2 contains a functional MTS that targets the mtSBP2-GFP protein to the mitochondria, and also that endogenous mtSBP2 localizes to the mitochondria. Although the EC1 antibody did detect full-length SBP2 by western blotting, we were unable to confirm the presence of mtSBP2 isoform in mitochondrial fractions of cells by this method.
###end p 53
###begin title 54
Coordinated transcriptional and translational regulation of SBP2 following UVA treatment
###end title 54
###begin p 55
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 239 247 239 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 500 501 500 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 501 503 501 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8226;&#8722;</sup>
###xml 599 600 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 679 687 679 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 692 702 692 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 965 973 965 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1323 1331 1311 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1377 1379 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1505 1513 1493 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1669 1677 1657 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2158 2159 2134 2135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 2160 2162 2136 2138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 2165 2174 2141 2150 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 2385 2386 2361 2362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2445 2448 2421 2424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 2588 2591 2564 2567 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 2985 2988 2961 2964 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 2174 3192 2150 3168 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="56">Coordinated transcriptional and translational regulation of SBP2 following UVA treatment. Transcriptional and translational response of full-length SBP2 (FLBSP2) and mitochondrial SBP2 (mtSBP2) following 50 kJ/m<sup>2</sup> of UVA irradiation was monitored in HeLa cells over 24 h. <bold>(A)</bold> Real-time RT-PCR using transcript specific primers shows a similar transcriptional induction of both transcripts in response to treatment. <bold>(B)</bold> Western blot using anti-SBP2 antibodies shows the translational response of endogenous SBP2 and HSP70 at different time points after UVA irradiation. Quantitation of FLSBP2 transcript and protein levels is presented in the graph below. Error bars represent the standard error of the mean (SEM). Transcript levels were normalized against GAPDH and protein levels were normalized against actin. <bold>(C)</bold> Western blots show the translational response of WT, Ex2ATG&gt;CTG and Ex3AG&gt;AA minigene-derived proteins to UVA treatment. HSP70 was used as a marker for UVA-induced stress and actin shows protein loading.</p>
###xml 2174 3192 2150 3168 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="56">Coordinated transcriptional and translational regulation of SBP2 following UVA treatment. Transcriptional and translational response of full-length SBP2 (FLBSP2) and mitochondrial SBP2 (mtSBP2) following 50 kJ/m<sup>2</sup> of UVA irradiation was monitored in HeLa cells over 24 h. <bold>(A)</bold> Real-time RT-PCR using transcript specific primers shows a similar transcriptional induction of both transcripts in response to treatment. <bold>(B)</bold> Western blot using anti-SBP2 antibodies shows the translational response of endogenous SBP2 and HSP70 at different time points after UVA irradiation. Quantitation of FLSBP2 transcript and protein levels is presented in the graph below. Error bars represent the standard error of the mean (SEM). Transcript levels were normalized against GAPDH and protein levels were normalized against actin. <bold>(C)</bold> Western blots show the translational response of WT, Ex2ATG&gt;CTG and Ex3AG&gt;AA minigene-derived proteins to UVA treatment. HSP70 was used as a marker for UVA-induced stress and actin shows protein loading.</p></caption>
###xml 3192 3192 3168 3168 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn829f5"/>
###xml 2165 3192 2141 3168 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="56">Coordinated transcriptional and translational regulation of SBP2 following UVA treatment. Transcriptional and translational response of full-length SBP2 (FLBSP2) and mitochondrial SBP2 (mtSBP2) following 50 kJ/m<sup>2</sup> of UVA irradiation was monitored in HeLa cells over 24 h. <bold>(A)</bold> Real-time RT-PCR using transcript specific primers shows a similar transcriptional induction of both transcripts in response to treatment. <bold>(B)</bold> Western blot using anti-SBP2 antibodies shows the translational response of endogenous SBP2 and HSP70 at different time points after UVA irradiation. Quantitation of FLSBP2 transcript and protein levels is presented in the graph below. Error bars represent the standard error of the mean (SEM). Transcript levels were normalized against GAPDH and protein levels were normalized against actin. <bold>(C)</bold> Western blots show the translational response of WT, Ex2ATG&gt;CTG and Ex3AG&gt;AA minigene-derived proteins to UVA treatment. HSP70 was used as a marker for UVA-induced stress and actin shows protein loading.</p></caption><graphic xlink:href="gkn829f5"/></fig>
We previously showed that SBP2 is regulated through redox-state and localization changes, and that these affect selenoprotein synthesis (14). In this study, we wished to investigate if oxidative stress may cause transcriptional changes in SECISBP2 expression, particularly in the full-length and mitochondrial transcripts. To complement our previous data, we used UVA irradiation, a physiologically relevant oxidative stress inducer that causes intracellular damage by production of oxygen singlet (O2*-) molecules. To monitor the transcriptional response of SBP2, HeLa cells were exposed to 50 kJ/m2 UVA irradiation and allowed to recover for the indicated amounts of time, and SECISBP2 and mtSECISBP2 transcript levels were measured by real-time RT-PCR. Interestingly, we found that both transcripts were induced by almost 3-fold immediately after UVA treatment, followed by a sharp decline at 2 h and subsequent stabilization of both transcripts for up to 24 h (Figure 5A). Importantly, these results show that both transcripts are regulated in a similar manner in response to oxidative stress. The response to UVA treatment at the protein level correlates well with the transcriptional response. We observed a rapid degradation of SBP2 with levels down to approximately30% of mock-treated cells at 0 h after treatment (Figure 5B). Interestingly and as reported previously (33), the stress sensor HSP70 protein was stabilized in response to UVA treatment and remained elevated for 16 h post treatment (Figure 5B). We believe that the rapid degradation of SBP2 during the course of UVA irradiation is the trigger for the concomitant transcriptional induction seen in Figure 5A. Although, SBP2 protein levels recovered slightly at 2 h post treatment, they remained at only approximately50% of the initial levels for up to 8 h and returned to the initial starting levels by 24 h post treatment. These results are consistent with our previous observations that selenoprotein synthesis is inhibited in response to oxidative stress and suggest that down regulation of SBP2 protein levels might provide additional mechanistic explanation for those observations (6,14). Figure 5.Coordinated transcriptional and translational regulation of SBP2 following UVA treatment. Transcriptional and translational response of full-length SBP2 (FLBSP2) and mitochondrial SBP2 (mtSBP2) following 50 kJ/m2 of UVA irradiation was monitored in HeLa cells over 24 h. (A) Real-time RT-PCR using transcript specific primers shows a similar transcriptional induction of both transcripts in response to treatment. (B) Western blot using anti-SBP2 antibodies shows the translational response of endogenous SBP2 and HSP70 at different time points after UVA irradiation. Quantitation of FLSBP2 transcript and protein levels is presented in the graph below. Error bars represent the standard error of the mean (SEM). Transcript levels were normalized against GAPDH and protein levels were normalized against actin. (C) Western blots show the translational response of WT, Ex2ATG>CTG and Ex3AG>AA minigene-derived proteins to UVA treatment. HSP70 was used as a marker for UVA-induced stress and actin shows protein loading.
###end p 55
###begin p 56
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 271 274 271 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 414 417 414 417 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 811 814 811 814 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
Coordinated transcriptional and translational regulation of SBP2 following UVA treatment. Transcriptional and translational response of full-length SBP2 (FLBSP2) and mitochondrial SBP2 (mtSBP2) following 50 kJ/m2 of UVA irradiation was monitored in HeLa cells over 24 h. (A) Real-time RT-PCR using transcript specific primers shows a similar transcriptional induction of both transcripts in response to treatment. (B) Western blot using anti-SBP2 antibodies shows the translational response of endogenous SBP2 and HSP70 at different time points after UVA irradiation. Quantitation of FLSBP2 transcript and protein levels is presented in the graph below. Error bars represent the standard error of the mean (SEM). Transcript levels were normalized against GAPDH and protein levels were normalized against actin. (C) Western blots show the translational response of WT, Ex2ATG>CTG and Ex3AG>AA minigene-derived proteins to UVA treatment. HSP70 was used as a marker for UVA-induced stress and actin shows protein loading.
###end p 56
###begin p 57
###xml 392 400 392 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
We also investigated the UVA stress response pattern of the SBP2 isoforms expressed by the minigene constructs. We conducted a similar time course experiment in response to UVA treatment in HeLa cells expressing wild-type SBP2 protein (WT-SBP2GFP), the exon 2 ATG>CTG mutated SBP2 (ATGm-SBP2GFP) and the SBP2 mutated protein that initiates translation from exon 3b (E3b-SBP2GFP). As shown in Figure 5C, all minigene products showed a similar down-regulation pattern in response to stress, as seen for endogenous SBP2. Similar results were obtained in NFF cells (data not shown). From these experiments we thus conclude that mutation of the ATG codon in exon 2 and thus the lack of mtSBP2 expression does not affect the response of the full-length SBP2 to UVA-induced oxidative stress, and that the spliced variants E3b-SBP2GFP and E5-SBP2GFP (data not shown) have a similar pattern of regulation as full-length SBP2 in response to stress. Importantly, these experiments established a coordinated transcriptional and translational mechanism of SBP2 regulation in response to oxidative stress, and revealed that the alternatively spliced transcripts and the corresponding proteins have a similar pattern of regulation as the full-length SBP2.
###end p 57
###begin title 58
DISCUSSION
###end title 58
###begin p 59
###xml 317 325 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 600 607 600 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 612 621 612 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 648 656 648 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 537 543 <span type="species:ncbi:9606">humans</span>
###xml 642 647 <span type="species:ncbi:9606">human</span>
SBP2 is a critical factor for selenoprotein synthesis, with roles in SECIS element binding, ribosome binding and Sec incorporation. Much of recent work has elaborated on understanding its role in the translation of 25 mammalian selenoproteins, by detailed molecular and biochemical characterization. Mutations in the SECISBP2 gene that either alter the reading frame through splicing defects or alter the interaction of SBP2 with a subset of SECIS elements due to amino acid substitutions, result in abnormal thyroid hormone function in humans (15,25). In this study, we presented the first detailed in vivo and in silico characterization of human SECISBP2 alternative splicing and highlighted a new mode of transcriptional and translational regulation. Interestingly and intriguingly, the most abundant SBP2 variant after the full-length SBP2 contains a MTS, which we showed is functional and required for targeting of the mtSBP2 protein to mitochondria. A small proportion of the endogenous SBP2 pool is also localized to the mitochondria, however, only a small fraction of cells appeared to have strong mitochondrial SBP2 localization. This suggests that the mitochondrial localization of SBP2 may be tightly regulated and may occur predominantly during certain, yet unidentified conditions.
###end p 59
###begin p 60
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1094 1099 1094 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35 B36 B37">35&#8211;37</xref>
###xml 1201 1203 1201 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1727 1728 1727 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1729 1731 1729 1731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 1806 1808 1806 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1847 1849 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 3286 3288 3286 3288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 4231 4239 4231 4239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 4244 4254 4244 4254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 409 414 <span type="species:ncbi:9606">human</span>
###xml 562 567 <span type="species:ncbi:9606">human</span>
The identification of a potential mitochondrial human-specific SBP2 isoform was an intriguing and somewhat puzzling finding when viewed against the known SBP2 function in decoding UGA as Sec during selenoprotein translation. This process is unlikely to occur within the inner mitochondria for the following reasons: (i) analysis of the mitochondrial genome using the SECISearch program (34) suggests that the human mitochondrial genome does not contain any genes with SECIS elements and hence does not encode selenoproteins; (ii) UGA codes for tryptophan in the human mitochondrial genome; and (iii) mitochondrial matrix translation uses a mechanism similar to that of prokaryotes. These facts would argue against the requirement of a mitochondrial SBP2 isoform with canonical function in Sec incorporation. However, emerging evidence suggests that translationally active cytoplasmic ribosomes, or polysomes, are present on the outer membrane of the mitochondria and that about 50% of mRNAs coding for mitochondria-localized products are primarily associated with mitochondria-bound polysomes (35-37). Targeting mRNAs to the mitochondria is mediated by conserved secondary structures in their 3' UTR (36). Although this process is poorly understood, it is possible that the conservation of localized translation might assist in the co-translational import of hydrophobic proteins into mitochondria to prevent their aggregation in the cytoplasm, or to simply provide a more efficient way of translation, as one mRNA molecule can serve in several rounds of translation. The mitochondrial SBP2 isoform could thus function in the translation of selenoproteins targeted to mitochondria such as thioredoxin reductase 2 (TxnRd2/TR3) (1,38), mitochondrial form of phospholipid glutathione peroxidase (PHGPx/GPx4) (39) and glutathione peroxidase 1 (GPx1) (40) on mitochondria-bound cytoplasmic ribosomes. Alternatively, mtSBP2 could be involved in binding to mRNA structures, possibly also in non-selenoprotein encoding mRNAs that target the message to the outer mitochondrial ribosomes. The high-resolution images we obtained of both over-expressed mtSBP2-GFP and endogenous mtSBP2 pointed to a localization of the mtSBP2 isoform on the outer mitochondrial surface, in specific punctate clusters. This localization would indeed be in agreement with the functional localization of SBP2 at polysomes. The fact that we could not detect mtSBP2 in mitochondrial subfractions of cells by western blotting argues for a possible loose interaction between mtSBP2 and the organelle, which may be easily disrupted during the fractionation procedure. But if mtSBP2 is localized on the outer surface of the mitochondria, why would it require a classical type of MTS that generally targets proteins to the inner mitochondrial matrix? Although this question remains to be answered, our findings are relevant to a recent report showing that DAKAP1, a multifunctional protein with roles in cAMP dependent protein kinase (PKA) regulation and mRNA binding, can be targeted to the cytosolic side of the outer membrane of the mitochondria by use of a classical MTS. DAKAP1 contains a bi-functional targeting motif that switches to encode either an MTS, such as the one present in mtSBP2, or an ER targeting signal (41). Although the precise mechanism of how this protein attaches to the mitochondria outer membrane remains unknown at present, it is possible to reconcile the idea that proteins that localize on the cytosolic side of the mitochondrial membrane can be targeted there by classical MTSs. The MTS in mtSBP2 may thus facilitate the localization of the protein to the cytosolic side of the mitochondria via active mitochondrial import. More detailed studies will be required to investigate this aspect of mtSBP2 localization as well as the precise role of this isoform in the cell. The low expression of mtSBP2 isoform in the cell lines tested indicates that its synthesis could be dependent on tissue-specific translation factors and may be maximized in tissues or organs with high demand for mitochondrial selenoproteins. A prime candidate would be testis, where PHGPx is the most abundant selenoprotein. Indeed, the expression of both full-length SECISBP2 and mtSECISBP2 transcripts was highest in testis when compared to twelve other tissues, providing additional proof to strengthen this hypothesis.
###end p 60
###begin p 61
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 269 276 269 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 644 652 644 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 737 743 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 866 873 866 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1130 1132 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1188 1195 1188 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1429 1436 1429 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1626 1628 1626 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1629 1631 1629 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 28 33 <span type="species:ncbi:9606">human</span>
This study established that human SECISBP2 has an extensive alternative splicing pattern in the 5'-region. Some of the splicing events provoke ORF alterations, which lead to premature termination codons, thus promoting translation from downstream ATG start codons. Our in vivo splicing assay and treatment with ASOs showed that at least four additional ATG start codons in exons 2, 3a, 3b and 5 are used to produce proteins with different N-terminal amino acid sequence such as mtSBP2, or N-terminally truncated SBP2 isoforms. Because all alternative splicing events within SBP2 are confined within the region dispensable for Sec incorporation in vitro, it is reasonable to postulate that these events are unlikely to affect RNA binding per se, however, this level of regulation may play a fine-tuning or regulatory role in SBP2-dependent Sec incorporation function in vivo. The role of the N-terminal region of SBP2 is a puzzling, yet unanswered, question in the field. So far, the only characterized motif within this region is a nuclear localization signal (NLS) that enables SBP2 to shuttle between the nucleus and cytoplasm (14), however, its requirement for selenoprotein synthesis in vivo has not been determined. Interestingly, the NLS is located within exon 8, which is common to all alternatively spliced SBP2 isoforms suggesting that this motif may indeed play an important role in the function of SBP2 in the nucleus in vivo. Consistent with this, recent studies have suggested a new role of SBP2 in protection of selenoprotein encoding mRNAs from nonsense mediated decay by binding to these mRNAs in the nucleus (42,43).
###end p 61
###begin p 62
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human selenoproteome consists of 25 selenoproteins (44) but the SECIS core element and the binding site for SBP2 are well conserved. As a result, Sec incorporation with regard to SECIS element binding would not require variability within the SBP2 RNA binding region which could explain the lack of alternate splicing in the C-terminal region of SBP2. In contrast, the hierarchy of selenoprotein synthesis is expected to involve specific factors that may dictate the differential binding of SBP2 to different selenoprotein mRNAs (25,43). The high sequence variability in the N-terminal region of SBP2 could thus serve as a protein-protein interaction domain and function in the recruitment of such factors prior to interaction with the SECIS element.
###end p 62
###begin p 63
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 463 471 463 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 476 486 476 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
In a previous study we showed that acute oxidative stress caused by H2O2 and sodium selenite had an inhibitory effect on selenoprotein synthesis, and that this was mediated by oxidation of SBP2 redox-sensitive cysteine residues and its depletion from the ribosomes (14). In the current study, using UVA-irradiation as a cause of oxidative stress we found that SBP2 responded by coordinated transcriptional and translational changes following stress. Importantly, SECISBP2 and mtSECISBP2 transcripts were simultaneously and immediately induced during treatment, and stabilized during the recovery phase. At the protein level, SBP2 was degraded and levels remained approximately half of the initial levels for approximately16 h post-irradiation. The SBP2 isoforms that we could monitor using the minigene showed similar down-regulation as full-length SBP2, suggesting that their intracellular function is most likely related to the function of full-length SBP2 in SECIS binding and Sec incorporation. However, our data does not exclude the possibility that mtSBP2 or any other SBP2 isoforms may perform additional functions unrelated to selenium metabolism.
###end p 63
###begin p 64
###xml 108 116 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
###xml 225 235 225 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mtSECISBP2</italic>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 757 765 757 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SECISBP2</italic>
This is the first report validating the occurrence and significance of alternative splicing associated with SECISBP2, an essential gene linked to selenium metabolism. Although, we have focussed mainly on one spliced variant, mtSECISBP2, there remain other variants of significant interest. Having shown that an ASO-based approach could be used to generate specific spliced variants, future studies could be tailored to examine their functions. Recent years have seen a dramatic evolution in our understating of translational regulation by microRNAs, a class of small RNA that could be synthesized by a stem-loop containing transcript generated from RNA Polymerase II (45). To a broader significance, it remains to be seen if some of the poorly translatable SECISBP2 spliced variants including mtSBP2 are meant to generate microRNAs and/or serve as potential targets of microRNAs.
###end p 64
###begin title 65
SUPPLEMENTARY DATA
###end title 65
###begin p 66
 are available at NAR Online.
###end p 66
###begin title 67
FUNDING
###end title 67
###begin p 68
###xml 88 117 88 117 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health</grant-sponsor>
###xml 126 137 126 137 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R01NS055925</grant-num>
###xml 142 153 142 153 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R21NS055149</grant-num>
The National Health and Medical Research Council of Australia (to KK.K.); United States National Institutes of Health grants (R01NS055925 and R21NS055149 to R.N.S). Funding for open access charge: Waived by Oxford University Press.
###end p 68
###begin p 69
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[Supplementary Data]
###end title 71
###begin title 72
ACKNOWLEDGEMENTS
###end title 72
###begin p 73
###xml 124 129 <span type="species:ncbi:9606">human</span>
We thank Dr Anna-Klara Rundlof for help with database searches and analyses, Dr Nathan Subramaniam for kindly providing the human cDNA panel and Drs. Armando van der Horst and Derek Richard for critical reading of the manuscript.
###end p 73
###begin title 74
REFERENCES
###end title 74
###begin article-title 75
Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon, UGA
###end article-title 75
###begin article-title 76
Recognition of UGA as a selenocysteine codon in type I deiodinase requires sequences in the 3' untranslated region
###end article-title 76
###begin article-title 77
Functional characterization of the eukaryotic SECIS elements which direct selenocysteine insertion at UGA codons
###end article-title 77
###begin article-title 78
Recoding elements located adjacent to a subset of eukaryal selenocysteine-specifying UGA codons
###end article-title 78
###begin article-title 79
A recoding element that stimulates decoding of UGA codons by Sec tRNA[Ser]Sec
###end article-title 79
###begin article-title 80
###xml 72 77 <span type="species:ncbi:9606">human</span>
From selenium to selenoproteins: synthesis, identity, and their role in human health
###end article-title 80
###begin article-title 81
Purification, redox sensitivity, and RNA binding properties of SECIS-binding protein 2, a protein involved in selenoprotein biosynthesis
###end article-title 81
###begin article-title 82
A novel RNA binding protein, SBP2, is required for the translation of mammalian selenoprotein mRNAs
###end article-title 82
###begin article-title 83
Characterization of mSelB, a novel mammalian elongation factor for selenoprotein translation
###end article-title 83
###begin article-title 84
Decoding apparatus for eukaryotic selenocysteine insertion
###end article-title 84
###begin article-title 85
Ribosomal protein L30 is a component of the UGA-selenocysteine recoding machinery in eukaryotes
###end article-title 85
###begin article-title 86
Biosynthesis of selenocysteine on its tRNA in eukaryotes
###end article-title 86
###begin article-title 87
Insight into mammalian selenocysteine insertion: domain structure and ribosome binding properties of Sec insertion sequence binding protein 2
###end article-title 87
###begin article-title 88
The redox state of SECIS binding protein 2 controls its localization and selenocysteine incorporation function
###end article-title 88
###begin article-title 89
Mutations in SECISBP2 result in abnormal thyroid hormone metabolism
###end article-title 89
###begin article-title 90
Understanding alternative splicing: towards a cellular code
###end article-title 90
###begin article-title 91
###xml 124 129 <span type="species:ncbi:9606">human</span>
Categorization and characterization of transcript-confirmed constitutively and alternatively spliced introns and exons from human
###end article-title 91
###begin article-title 92
###xml 97 103 <span type="species:ncbi:9606">humans</span>
Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans
###end article-title 92
###begin article-title 93
###xml 22 27 <span type="species:ncbi:9606">human</span>
Pre-mRNA splicing and human disease
###end article-title 93
###begin article-title 94
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
###end article-title 94
###begin article-title 95
CD44 in cancer
###end article-title 95
###begin article-title 96
Frequent association of alternative splicing of NER, a nuclear hormone receptor gene in cancer tissues
###end article-title 96
###begin article-title 97
Emerging roles of BRCA1 alternative splicing
###end article-title 97
###begin article-title 98
###xml 99 104 <span type="species:ncbi:9606">human</span>
Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences
###end article-title 98
###begin article-title 99
Altered RNA Binding Activity Underlies Abnormal Thyroid Hormone Metabolism Linked to a Mutation in Selenocysteine Insertion Sequence-binding Protein 2
###end article-title 99
###begin article-title 100
A catalogue of splice junction sequences
###end article-title 100
###begin article-title 101
Diversity and functional plasticity of eukaryotic selenoproteins: identification and characterization of the SelJ family
###end article-title 101
###begin article-title 102
The prokaryotic selenoproteome
###end article-title 102
###begin article-title 103
The microbial selenoproteome of the Sargasso Sea
###end article-title 103
###begin article-title 104
###xml 31 36 <span type="species:ncbi:9606">human</span>
Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron
###end article-title 104
###begin article-title 105
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing
###end article-title 105
###begin article-title 106
The L7Ae RNA binding motif is a multifunctional domain required for the ribosome-dependent Sec incorporation activity of Sec insertion sequence binding protein 2
###end article-title 106
###begin article-title 107
The expression of genes induced in melanocytes by exposure to 365-nm UVA: study by cDNA arrays and real-time quantitative RT-PCR
###end article-title 107
###begin article-title 108
New mammalian selenocysteine-containing proteins identified with an algorithm that searches for selenocysteine insertion sequence elements
###end article-title 108
###begin article-title 109
###xml 42 47 <span type="species:ncbi:4932">yeast</span>
Genome-wide analysis of mRNAs targeted to yeast mitochondria
###end article-title 109
###begin article-title 110
Why are many mRNAs translated to the vicinity of mitochondria: a role in protein complex assembly?
###end article-title 110
###begin article-title 111
###xml 105 110 <span type="species:ncbi:4932">yeast</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
The role of the 3' untranslated region in mRNA sorting to the vicinity of mitochondria is conserved from yeast to human cells
###end article-title 111
###begin article-title 112
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization
###end article-title 112
###begin article-title 113
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat phospholipid-hydroperoxide glutathione peroxidase. cDNA cloning and identification of multiple transcription and translation start sites
###end article-title 113
###begin article-title 114
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
The Gpx1 gene encodes mitochondrial glutathione peroxidase in the mouse liver
###end article-title 114
###begin article-title 115
A Molecular Switch for Targeting between Endoplasmic Reticulum (ER) and Mitochondria: conversion of a mitochondria-targeting element into an ER-targeting signal inIN DAKAP1
###end article-title 115
###begin article-title 116
Nuclear assembly of UGA decoding complexes on selenoprotein mRNAs: a mechanism for eluding nonsense-mediated decay?
###end article-title 116
###begin article-title 117
SBP2 binding affinity is a major determinant in differential selenoprotein mRNA translation and sensitivity to nonsense-mediated decay
###end article-title 117
###begin article-title 118
Characterization of mammalian selenoproteomes
###end article-title 118
###begin article-title 119
Genomics of microRNA
###end article-title 119

